{
  "FOCUS": "randomized controlled multicenter comparing efficacy safety adalimumab mycophenolate mofetil steroid dependent non infectious uveitis focus first prospective randomized comparing standard care mycophenolate mofetil adalimumab recently active non infectiuous uveitis neutrophil immune unit steroid dependency firm evidence randomized trial compared classical immunosuppressive compound biological agent identified best condition burden neutrophil immune unit reduced use immunosuppressive agent biologics raising question compound preferentially used recently active neutrophil immune unit steroid dependency objective objective compare efficacy adalimumab milligrams day milligrams day subcutaneously standard care mycophenolate mofetil day orally week recently active non infectious intermediate posterior uveitis pan uveitis steroid dependency endpoint efficacy endpoint failure rate week failure defined following least one eye new active inflammatory chorioretinal retinal vascular lesion worsening best corrected visual acuity best corrected visual acuity line step increase anterior chamber cell grade vitreous haze relative baseline objective comparing adalimumab milligrams day milligrams day subcutaneously standard care mycophenolate mofetil day orally week evaluate cumulative incidence failure evaluate change best corrected visual acuity best corrected visual acuity logmar baseline week evaluate change ocular inflammation anterior chamber vitreous baseline week evaluate change sign including vessel leakage baseline week evaluate presence macular edema baseline week evaluate quality life related uveitis evaluate steroid sparing effect baseline evaluate number time relapse uveitis characteristic uveitis worsening baseline evaluate effect underlying systemic disease appropriate baseline evaluate safety adalimumab mycophenolate mofetil endpoint time failure logmar best corrected visual acuity eye anterior chamber cell grade vitreous haze grade standardization of uveitis nomenclature criterion eye central retinal thickness eye baseline proportion central macular thickness micron time optical coherence tomographic optical coherence tomography evidence macular edema least one eye national eye institute visual functioning questionaire vfq composite score measure corticosteroid sparing percent meeting target milligrams kilograms day prednisone mean change mean dose week cumulative dose cumulative incidence relapse number relapse manifestation underlying disease depending underlying disease evaluated safety tolerability treatment assessed frequency severity adverse event discontinuation baseline week prospective iii multicenter open label two arm randomized comparing efficacy safety adalimumab standard care mycophenolate mofetil subject recently active intermediate posterior uveitis pan uveitis despite steroid use oral prednisone milligrams day equivalent oral corticosteroid stable dose least week prior first drug administration day adult recently active non infectious uveitis neutrophil immune unit despite oral prednisone milligrams day recently active disease defined presence least following parameter either eye within prior visit active chorioretinal retinal vascular lesion presence macular edema optical coherence anterior chamber cell standardization uveitis nomenclature standardization of uveitis nomenclature criterion vitreous haze national eye institute national eye institute standardization of uveitis nomenclature criterion eligibility criterion checked screening visit take place four week maximum prior visit randomization visit adult meeting following criterion may included provide written prior performance specific procedure age diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criterion standardization uveitis nomenclature standardization of uveitis nomenclature criterion posterior pan uveitis confirmed documented medical history recent activity neutrophil immune unit defined presence least following parameter either eye within prior visit despite milligrams day oral prednisone active chorioretinal retinal vascular lesion presence macular edema optical coherence anterior chamber cell standardization uveitis nomenclature standardization of uveitis nomenclature criterion vitreous haze national eye institute national eye institute standardization of uveitis nomenclature criterion chest ray postero anterior lateral ct scanner result within week prior evidence active tuberculosis active infection malignancy potential subject positive interferon gamma release assay igra quantiferon tuberculosis gold spot tuberculosis test eligible chest ray show evidence suggestive active tuberculosis disease sign symptom pulmonary extra pulmonary tuberculosis disease subject latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course female subject child bearing potential negative pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner becoming pregnant stopping therapy mycophenolate mofetil adalimumab respectively unless sterility confirmed simultaneous use two complementary method contraception preferable method may considered highly effective method achieve failure rate less per used consistently correctly considered highly effective birth control method according ctfg recommendation method include female subject combined estrogen progestogen containing hormonal contraceptionassociated inhibition ovulation oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire associated treatment reliability sexual abstinence need evaluated relation duration preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence affiliated social security system subject included meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permitted isolated anterior uveitis monocular active tuberculosis positive human immunodeficiency virus serology hcv hb ag test history malignancy within prior carcinoma situ cervix non metastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody mycophenolate mofetil rifampicin isoniazid fluorescein infection requiring intravenous antibiotic within week prior history multiple sclerosis demyelinating disorder laboratory value assessed hemoglobin deciliter white blood cell count millimeter platelet count millimeter glomerular filtration rate gfr ml min transaminase time upper normal value use following systemic treatment specified systemic alkylating agent within prior cyclophosphamide chlorambucil live attenuated vaccine within week prior stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency pregnancy breastfeeding legal protection another interventional involving human participant exclusion end previous involving human participant applicable eligible recently active neutrophil immune unit randomized ratio arm adalimumab milligrams day milligrams day subcutaneously arm standard care defined mycophenolate mofetil day orally week group receive corticosteroid regimen neutrophil immune unit receive oral prednisone milligrams day oral corticosteroid equivalent maximum milligrams day prednisone common prednisone tapering programme applied group decrease discontinuation week week long disease inactive arm standard care defined mycophenolate mofetil day orally week adalimumab milligrams day milligrams day subcutaneously visit week week hcg plasmatic urine pregnancy test urine pregnancy test week monthly week stopping mycophenolate mofetil therapy stopping adalimumab therapy unless menopause sterility confirmed fundoscopy optical coherence tomography optical coherence tomography week retinal angiography week quality of life questionnaire week refractory non infectious uveitis serious ocular pathology accounting blindness case reliable data required uveitis particularly use biotherapies corticosteroid immunosuppressant shown sustained remission rate severe refractory relapsing uveitis incidence blindness uni reduced recent use biotherapies raising question whether therapy prescribed earlier management severe non infectious uveitis compared conventional immunosuppressant biotherapies fast acting highly effective corticosteroid sparing thus limiting cataract cortico induced glaucoma focus first randomized comparing efficacy safety adalimumab standard care mycophenolate mofetil maintenance corticosteroid dependent uni validate optimize hard treat uveitis may also confirm whether adalimumab superior mycophenolate mofetil term efficacy allow direct comparison safety profile treatment could significantly improve management corticosteroid dependent uni finally help selection best prevent onset blindness side effect difficult treat case expected benefit individual reducing morbidity non infectious uveitis collective reducing cost unemployment disability hospitalization caused uni associated toxicity investigational drug associated use concomitant medication level collection free eligible randomized one group randomization visit arm adalimumab milligrams day milligrams day subcutaneously arm mycophenolate mofetil day orally week receive corticosteroid regimen receive corticosteroid milligrams day following schedule reduction prednisone apply group decrease discontinuation week week long disease inactive arm multicenter national including center recruitment centre duration duration week week duration center prospective two arm randomized open label iii comparing adalimumab standard care mycophenolate mofetil based binary endpoint failure week randomization stratified macular oedema steroid dose conducted using group sequential design one interim analysis observation completed efficacy futility early stopping rule specifically assuming probability failure endpoint soc control population versus alternative hypothesis adalimumab number per randomization arm required ensure power one sided type error accounting one interim analysis observation completed using lan demets obrien fleming type spending function define efficacy futility non binding early stopping rule moreover plan include per randomization arm account potential lost follow",
  "MARVEL": "exploring venlafaxine pharmacokinetic variability phenotyping approach regarding direct cost social value depression decision antidepressant prescription must optimized much possible development personalized medicine psychiatry may reduce failure intolerance resistance hence burden cost affective disorder hope biomarkers found guide selection might decisive interest able assess individual metabolism activity propose explore relationship activity drug metabolizing enzyme dme transporter assessed phenotypic approach efficacy antidepressant focus venlafaxine provides reasonable second step choice depression used extensively psychiatric practice metabolism involves several cytochrome cyp enzyme transporter general practitioner correlation concentration metabolite odesmethylv odv drug metabolism variability assessed phenotypic approach compare responder non responder well without side effect cyp activity prevalence profile metabolism cyp activity prevalence profile metabolism cyp activity prevalence profile metabolism general practitioner activity prevalance profile transport correlation odv concentration dose odv concentration antidepressant efficacy tolerance correlation ratio odv cyp activity correlation concentration hour area under the curve hour metabolic ratio hydroxyomeprazole omeprazole conduct exploratory association analysis blood biomarkers candidate mrna mirna tolerance efficacy analyse role genetic variation dna determination cyp phenotype picomolar profile odv concentration cyp activity hydroxyomeprazole omeprazole hour area under the curve metabolic ratio hour omeprazole oral administration cyp activity dextrorphan dextromethorphan ratio two hour dextromethorphan oral administration cyp activity hydroxymidazolam midazolam ratio two hour midazolam oral administration general practitioner activity fexofenadine area under the curve based fexofenadine concentration hour fexofenadine oral administration antidepressant efficacy madrs hamd qids antidepressant tolerance prise fisber antidepressant observance mar circulating mrna mirna transcript allelic variation cyp cyp interventional recherche bio medicale major depressive disorder madrs despite week regardless dose hospitalized outpatient major depressive disorder madrs visit selection non responder week regardless dose decision psychiatrist increase dose visit selection male female age understanding french language able give written inform signed participate individual covered social security regimen treated one antidepressant mirtazapine mianserine currently treated one drug substrate cocktail esomeprazole sensitivity contra indication substrate drug used current pregnancy desire get pregnant breastfeeding bipolar disorder schizophrenia oral extended release venlafaxine regardless dose selection increased milligrams according psychiatric follow necessary assessment drug metabolizing enzyme activity given cocktail probe drug oral route one time capsule omeprazole milligrams ml oral liquid formulation dextromethorphane bromhydrate tussidane milligrams ml syrup milligrams injectable solution midazolam oral administration midazolam milligrams ml injectable solution tablet fexofenadine milligrams dosage venlafaxine odemethylv odv collect dna circulating mrna mirna transcript assessment drug efficacy tolerance adherence using standardized questionnaire administration cocktail drug current authorization two blood sample ml one blood sample ml one blood sample ml three blood spot risque selection visit take place usual medical follow include measurement madrs hamd score visit carried part traditional hospitalization needed regarding psychiatric condition conversely done day hospitalization consultation systematically supervised practitionner take place day increase dosage include verification non criterion signature screen tobacco use fagerstrom test characteristic mood disorder anxiety scale tyrer qids standard criterion rating medication trial antidepressant failure level resistance mar score prise score fisber score visit take place day visit include sampling dosage venlafaxine odemethylv odv collect dna circulating mrna mirna transcript phenotypic administration cocktail probe drug capsule omeprazole milligrams ml oral liquid formulation dextromethorphane bromhydrate tussidane milligrams ml syrup milligrams injectable solution midazolam oral administration midazolam milligrams ml injectable solution tablet fexofenadine milligrams pill liquid formulation taken orally successively glass water followed capillary blood sample hour cocktail administration drop hour small finger prick db device measurement cocktail drug concentration drug parent metabolite visit take place day week day week visit psychologist doctor included assessment drug efficacy tolerance adherence mar score prise score fisber score madrs hamd qids standard center france center investigation france center involved biological analysis france switzerland included subject length day maximal research day day center statistical analysis performed sample size reached end point measure available hypothesis prevalence cyp um profile twice high non responder comparison responder cyp metabolic profile comparable caucasian demonstrate prevalence two fold observed non responder type error statistical power sample size tabulated according prevalence response thus anticipate potential large disproportion responder non responder defined decided include allow control type type ii error rate comparison prevalence cyp um profile among group addition sample size allow sufficient number cyp picomolar intramuscular um determine effect cyp variation odv plasma level efficacy adverse event type error rate fixed test two sided compared thus multiple imputation popular approach handling pervasive problem missing data biostatistics used usually performed missing random mar assumption multiple imputation chained equation knowledge flexible approach handle complex pattern missing data including categorical data quantitative data survival data analysis performed intent treat basis exploratory analysis consider population compliers completed according scheduled protocol",
  "OPTISAGE": "iii comparing graft versus host disease prophylaxis anti thymoglobulin thymoglobulin anti-thymocyte lymphocyte globulin grafalon elderly acute myeloid leukemia myelodysplatic syndrome receiving allogeneic hematopoietic stem cell transplantation human leukocyte antigen matched unrelated donor following reduced intensity conditioning regimen fludarabine treosulfan allogeneic hematopoietic stem cell transplantation allo hematopoietic stem cell transplantation remains curative therapy acute myeloid leukemia acute myeloid leukemia myelodysplastic syndrome md requiring allo hematopoietic stem cell transplantation age transplanted reduced intensity conditioning ric regimen optimal ric graft versus host disease prophylaxis regimen allowing good control disease preventing graft versus host disease remains determined elderly iii comparing conventional ric fludarabine busulfan day fludarabine treosulfan demonstrated advantage flu treosulfan arm term event free survival event-free survival therefore considered new standard ric regimen acute myeloid leukemia md graft versus host disease prevention crucial role post transplant outcome potentially interfering graft versus leukemia gvl effect immune reconstitution anti thymocyte globulin anti thymoglobulin recommended reduce acute chronic graft versus host disease transplant performed matched unrelated donor however optimal type anti thymoglobulin approved brand anti thymoglobulin thymoglobulin anti-thymocyte lymphocyte globulin grafalon displaying distinct characteristic optimal dose anti thymoglobulin still unknown retrospective transplanted mainly ric matched related unrelated donor haematological malignancy observed anti-thymocyte lymphocyte globulin associated reduction grade ii intravenous infusion acute graft versus host disease comparison anti thymoglobulin without increasing incidence relapse iii randomized propose compare graft versus host disease prevention anti thymoglobulin versus anti-thymocyte lymphocyte globulin acute myeloid leukemia md age transplanted matched unrelated donor following fludarabine treosulfan ric hypothesis anti-thymocyte lymphocyte globulin would better control graft versus host disease population thus limiting morbidity mortality procedure main objective compare incidence grade ii intravenous infusion acute graft versus host disease day post transplantation md acute myeloid leukemia transplanted matched unrelated donor mud following reduced intensity conditioning fludarabine treosulfan receiving graft versus host disease prophylaxis anti thymoglobulin thymoglobulin versus anti-thymocyte lymphocyte globulin grafalon endpoint incidence grade ii intravenous infusion acute graft versus host disease according magic classification appendix section day post transplantation objective evaluate effect graft versus host disease prophylaxis engraftment graft failure evaluate effect graft versus host disease prophylaxis incidence grade acute graft versus host disease chronic graft versus host disease evaluate effect graft versus host disease prophylaxis incidence infection evaluate effect graft versus host disease prophylaxis progression free survival evaluate effect graft versus host disease prophylaxis relapse incidence evaluate effect graft versus host disease prophylaxis non relapse mortality evaluate effect graft versus host disease prophylaxis overall survival evaluate effect graft versus host disease prophylaxis graft versus host disease relapse free survival grfs evaluate effect graft versus host disease prophylaxis health related quality life fact bmt evaluate effect graft versus host disease prophylaxis chimerism evaluate effect graft versus host disease prophylaxis immune reconstitution nk regulatory cell level peripheral blood evaluate effect graft versus host disease prophylaxis day hospitalisation first post transplantation evaluate effect graft versus host disease prophylaxis incidence severity vod identify prognostic factor associated endpoint prophylaxis arm search covariate interaction endpoint evaluate effect graft versus host disease prophylaxis incidence late acute graft versus host disease day overlap syndrome chronic graft versus host disease endpoint hematopoietic recovery least consecutive day neutrophil platelet immune reconstitution analyzing nk regulatory cell gammaglobulin level peripheral blood post transplantation chimerism grade acute graft versus host disease incidence appendix section acute graft versus host disease treatment first line response steroid course refractory acute graft versus host disease chronic graft versus host disease incidence date grading nih classification appendix section relapse incidence relapse defined reappearance leukemic cell md feature allo hematopoietic stem cell transplantation bonne marrow cytology cytogenetic analysis bone marrow aspiration extra medullary site proven biopsy progression free survival severe infection ctae grade fully described incidence cmv ebv reactivations non relapse mortality overall survival graft versus host disease relapse free survival grfs defined alive without disease relapse without developed acute grade iii intravenous infusion severe chronic graft versus host disease health related quality life assessed using fact bmt questionnaire post transplantation number day hospitalization transplant hospitalization transplantation related complication incidence severity vod lymphocyte count standard blood count conditioning late acute graft versus host disease overlap syndrome chronic graft versus host disease iii multicenter randomized controlled open label comparing gvdh prophylaxis anti thymoglobulin versus anti-thymocyte lymphocyte globulin acute myeloid leukemia md transplanted mud following fludarabine treosulfan ric age presenting acute myeloid leukemia md indication allogeneic stem cell transplantation age unfit myeloblative conditioning acute myeloid leukemia requiring allogeneic stem cell transplantation intermediate high acute myeloid leukemia complete cytologic response complete remission md requiring allogeneic stem cell transplantation international prognostic scoring system international prognostic scoring system international prognostic scoring system feature rapide blast increase life threatening neutropenia thrombopenia high transfusion need without human leukocyte antigen matched related donor identified matched human leukocyte antigen unrelated donor usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) performans status severe uncontrolled infection cardiac left ventricular ejection fraction lung diffusing capacity of lung for carbon monoxide adequate organ function aspartate amino transferase alanine-aminotransferase bilirubin creatinine clearance ml min except abnormality linked hematological disease health insurance coverage signed written contraception method must prescribed duration research nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable implantable progestogen hormonal contraception intrauterine device intrauterine device intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom carcinoma last except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus htlv active hepatitis yellow fever vaccine others live virus vaccine within transplantation heart failure according “new york heart association” ii left ventricular ejection fraction lung diffusing capacity of lung for carbon monoxide preexisting acute hemorrhagic cystitis renal failure creatinine clearance ml min pregnancy hcg positive breast feeding debilitating medical psychiatric illness would preclude realization sct understanding protocol state medical aid legal protection protection court curatorship guardianship grafalon contraindication mentioned smpc grafalon thymoglobulin hypersensitivity rabbit protein excipients trial medicinal product human use exclusion end previous contraindication mentioned smpc auxiliary medicinal product planned used cyclosporine mycophenolate mofetil fludarabine treosulfan iii grafalon milligrams kilograms day intravenous infusion consecutive day day transplantation thymoglobuline milligrams kilograms intravenous infusion day transplantation conditionning regimen receive conditioning regimen fludarabine milligrams day intravenous infusion day day day treosulfan day intravenous infusion day day day donor stem cell source human leukocyte antigen matched unrelated donor gcsf mobilized peripheral blood stem cell accepted cd target dose kilograms body weight graft versus host disease prophylaxis prophylaxis graft versus host disease depend randomization arm anti-thymocyte lymphocyte globulin grafalon milligrams kilograms day intravenous infusion consecutive day day anti-thymocyte lymphocyte globulin grafalon anti thymoglobulin thymoglobuline anti thymoglobulin thymo two schedule administration anti thymocyte globulin anti thymoglobulin accepted milligrams kilograms day intravenous infusion consecutive day day milligrams kilograms intravenous infusion day followed milligrams kilograms intravenous infusion day milligrams kilograms day addition receive cyclosporine cyclosporine a milligrams kilograms day mycophenolate mofetil mycophenolate mofetil milligrams kilograms day follows cyclosporine a day progressive withdrawal starting post sct agvhd according practice center mycophenolate mofetil day day arm randomisation ratio anti thymoglobulin anti-thymocyte lymphocyte globulin graft versus host disease prophylaxis health related quality fact bmt life biological biocollection pharmacokinetic anti-thymocyte lymphocyte globulin frozen plasma ml tube ml edta day accordance decree february biocollection blood pbmcs plasma dry pellet ml tube ml edta point base line via cryostem ml tube ml edta accordance decree february bio collection peripheral blood mononuclear cell plasma dry pellet blood cell performed base line per arm future biological would performed finding complementary funding collection organized via cryostem order better understand modulation immune response two anti thymoglobulin brand plasma collection anti thymoglobulin pharmacokinetic analysis anti-thymocyte lymphocyte globulin arm sample collected administration anti-thymocyte lymphocyte globulin day day frozen center data analyzed according pre conditioning lymphocyte count correlated post transplant outcome graft versus host disease relapse non relapse related mortality able determine formula optimize anti-thymocyte lymphocyte globulin dose lymphocyte count future plasma collection start including finding complementary funding expect demonstrate benefice term reduction acute graft versus host disease anti-thymocyte lymphocyte globulin arm improve outcome elderly acute myeloid leukemia md france duration centre hypothesis based reduction incidence day post hematopoietic stem cell transplantation grade ii intravenous infusion acute graft versus host disease anti thymoglobulin arm anti-thymocyte lymphocyte globulin arm assuming randomised would reach transplant incidence competing death without graft versus host disease arm accounting competing two sided logrank test overall sample size subject control group group achieves power significance level detect hazard ratio follow time day included interim analysis scheduled performed",
  "FIBRAPLO": "haplo identical transplantation myelofibrosis prospective multicentric curative myelofibrosis allogeneic hematopoietic stem cell hematopoietic stem cell transplantation reported intermediate higher according international prognostic score benefit hematopoietic stem cell transplantation term survival kroger others conducted france prospective testing use ruxolitinib transplantation jak allo nct outcome better transplanted matched sibling donor unrelated donor confirming kroger others rondelli others jak allo acute graft versus host disease incidence high often hyperacute severe recently ebmt group reported registry familial haplo identical transplantation haplo myelofibrosis raj others post transplant cyclophosphamide used case one overall survival disease free survival disease-free survival favorably compared outcome unrelated transplantation genova team also reported impressive result haplo identical transplantation center bregante others bregante others reported outcome cohort transplanted main difference frequent use haplo second versus outcome much better second versus author suggest improvement related best outcome among haplo transplantation improvement outcome haplo attributed better graft versus host disease prophylaxis especially use post transplant cyclophosphamide given poor outcome unrelated transplantation especially human leukocyte antigen mismatched unrelated setting encouraging result family haplo identical transplantation current proposes test haplo identical transplantation myelofibrosis without matched related donor main objective disease free survival without rejection one haplo identical transplantation myelofibrosis main criterion judgement disease rejection free survival hematopoietic stem cell transplantation assess incidence acute graft versus host disease grade day incidence acute graft versus host disease grade day engraftment day incidence chronic graft versus host disease non relapse mortality overall survival relapse progression incidence rejection incidence time neutrophil engraftment day time platelet engraftment day infection incidence day cytokine profile transplantation day day day day day impact genetic alteration overall survival non relapse morality multicentric myelofibrosis contraindication transplant advanced disease international score could proposed human leukocyte antigen matched donor aged myelofibrosis myelofibrosis essential thrombocythemia polycythemia vera proven marrow biopsy myelofibrosis combine least following criterion constitutional symptom weight loss one fever without infection recurrent muscle bone join pain extreme fatigue anemia hemoglobin gr deciliter red blood cell transfusion requirement thrombocytopenia peripheral blast count least found time white blood cell count cytoreductive karyotype inv performance status according eastern cooperative oncology group (= performans status (= ecog)) health insurance coverage signed written woman agreed take nomegestrol acetate contraception treosulfan men agreed conceive child treosulfan myelofibrosis transformed acute leukemia poor performance status eastern cooperative oncology group (= performans status (= ecog)) cardiac failure ef currently past even corrected renal failure creatininemia mol clearance ml min respiratory function altered vital capacity forced expired volume biological significant liver abnormality aspartate amino transferase alanine-aminotransferase normal range bilirubin normal range human leukocyte antigen matched donor available tutorship curatorship unwilling unable comply protocol pregnant woman breastfeeding contraindication treosulfan hypersensitivity active substance active non controlled infectious disease fanconi anaemia dna breakage repair disorder administration live vaccine contraindication circumstance precludes use drug involved protocol especially thiotepa fludarabine treosulfan investigational medicinal product used conditioning regimen haplo identical transplantation treosulfan received eu wide approval toxicity reduced conditioning therapy prior allogeneic haematopoietic stem cell transplantation june provided medac treosuflan conditioning regimen administered followed gr per day intravenous infusion route used combination standard association thiotepa milligrams kilograms day fludarabine milligrams per day day day therefore thiotepa fludarabine indissociable treosulfan also considered medicinal product na haplo identical transplantation use treosulfan thiotepa fludarabine conditioning regimen additional plasma sample additional blood sample ml additional blood sample ml goal show haplo identical hematopoietic stem cell transplantation using thiotepa fludarabine combination treosulfan give acceptable result even better transplantation human leukocyte antigen mismatched donor close matched unrelated donor myelofibrosis follow followed transplantation analyze occurrence graft versus host disease survival relapse status duration per per site analysis based intent treat basis including whatever administered sensitivity analysis performed actually receive graft withdrawal positive report using data excluded baseline summary statistic namely percentage median interquartile range iqr performed right censored endpoint estimated using nonparametric method kaplan meier curve cumulative incidence curve considered case non informative informative censoring based log rank test gray test respectively adjustment potential confounders used cox proportional hazard model model assumption checked using test proportional hazard spline smoothing residual log linearity assumption statistical analysis performed sa sa inc cary nc http www project org software package",
  "CAMOVID": "camovid multicenter randomized evaluate efficacy safety camostat mesylate sars cov infection covid ambulatory adult since december novel coronavirus called sars cov severe acute respiratory syndrome coronavirus caused international outbreak respiratory illness described covid nd march confirmed case covid including death reported world health organization march severe case france including death spectrum symptomatic infection range mild critical infection severe infected require hospitalization require intensive care unit admission diagnosis sars cov infection relies symptom microbiological testing test sars cov infection testing center use reverse transcription polymerase chain reaction reverse-transcription polymerase chain reaction nasal swab productive cough number investigational agent explored antiviral covid however date controlled data supporting use specific anti viral drug immunomodulatory drug efficacy covid unknown sars cov infects human cell binding spike protein membranous aminopeptidase called ace angiotensin converting enzyme among tissue ace expression mainly found pneumocytes enterocytes renal tubular cell podocytes cellular entry sars cov requires protein priming cellular serine protease tmprss entail protein cleavage allows fusion viral cellular membrane murine model sars cov pneumonia iwata yoshikawa others showed tmprss ko mouse weakened inflammatory cytokine response reduced lung injury control mouse hoffmann others found tmprss inhibitor camostat mesylate blocked viral entry reduce infection human pneumocytes lung cell line sars cov also showed serum convalescent sars cross neutralized sars driven entry another performed bojkova others showed camostat mesylate reduced cytopathogenic effect due sars cov human colonic cell line camostat mesylate serine protease inhibitor commonly used japan dose milligrams day successfully safely used treat pancreatitis associated pain post operative reflux oesophagitis side effect reported rare dos nausea diarrhea hypersensitivity case cytopenia less hyperkaliemia abnormal hepatic function less hypothesize camostat mesylate initiated early sars cov infection reduce viral infection viral cytopathogenic effect blocking sars cov entry cell therefore prevent deterioration toward severe form covid objective evaluate efficacy camostat mesylate sars cov infection high adult confirmed covid requiring initial hospitalization term hospitalization need day randomization endpoint proportion hospitalized covid deterioration died without hospitalization day day indicative basis criterion hospitalization presence following respiratory rate min rest sp room air blood pressure mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly haut conseil à la santé publique reason requiring hospitalization left discretion physician objective adult diagnosed laboratory confirmed covid requiring initial hospitalization evaluate impact camostat mesylate compared placebo safety day efficacy term need hospitalization covid management independent blinded committee review overall improvement day efficacy term intensive care need day efficacy term time hospitalization day efficacy respiratory function day overall survival day randomization reported outcome initial symptom day virological serological immunological efficacy day including surrogacy assessment candidate marker day renal complication day liver complication day covid transmission within household endpoint adverse event aes number aes number serious aes saes investigational medication discontinuation reason day independent endpoint adjudication committee reviewed proportion hospitalized day day covid deterioration independent eac review patientsfiles blinded randomized group determine whether hospitalization criterion related covid covid improvement ordinal scale day admission intensive care unit within day number day alive without hospitalization day initiation invasive mechanical ventilation covid severe within day initiation oxygen therapy covid within day overall survival day number day alive without symptom day sars cov virological assessment day day day day nasal swab droplet quantification sars cov rnaemia sars cov serological assessment day day day day plasma il il tnfa il level day peripheral blood lymphocyte phenotyping telomere length measurement day day day acute kidney failure defined least serum creatinine increase milligrams deciliter time baseline oliguria ml kilograms kdigo scale within day serum electrolyte estimated glomerular filtration rate day liver transaminase gamma gt alkaline phosphatase day percentage covid affected individual sharing household day multicenter single blinded placebo controlled two arm parallel randomized iii ambulatory adult high laboratory confirmed covid requiring initial hospitalization old increased severe covid belonging one following group age body mass index kilograms diabetes hypertension chronic renal failure egfr ml min chronic heart disease asthma chronic obstructive pumonary disease cystic fibrosis chronic liver disease chronic neurological disease solid organ transplant bone marrow transplant sickle cell anemia major thalassemia active currently treated diagnosed cancer active currently treated diagnosed malignant blood disease immunosuppressive observed laboratory confirmed sars cov infection mild covid fulfilling following criterion positive sars cov rt pcr nasal saliva swab sample positive sars cov antigen test performed within visit symptom sign consistent sars cov infection including limited fever upper respiratory tract infection sign digestive sign muscle pain anosmia dysgueusia participate must able willing comply visit procedure initial need hospitalization covid management defined following severity criterion respiratory rate min rest sp room air blood pressure mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly recommendation haut conseil à la santé publique reason requiring immediate hospitalization left discretion physician pregnancy breastfeeding another interventional drug subject protected law guardianship curatorship absence health insurance known hypersensitivity camostat mesylate known person sharing household already included another covid ambulatory interventional completed full sars cov vaccine immunization procedure less week prior covid diagnosis last vaccine injection performed less week prior covid diagnosis camostat mesylate oral administration milligrams day milligrams every hour day day day placebo tablet following schedule investigational drug oral medication camostat mesylate placebo evaluate candidate therapeutic strategy context sars cov pandemic specifically proposed target ambulatory high newly diagnosed confirmed covid requiring initial hospitalization strategy aim improve short term outcome ambulatory prevent evolution severe form requiring hospitalization therefore participate reducing hospitalization need quantitative qualitative relieving healthcare system may reduce contagiosity moreover useful therapeutic option ambulatory early diagnosis management epidemic upcoming lockdown removal additional camostat mesylate known side effect digestive nausea vomiting diarrhea hypersensitivity cytopenia liver abnormal function hyperkaliemia level screened consults participating care general practitioner gps emergency department saint louis hospital bichat hospital mondor hospital argenteuil hospital hospital outpatientcovid screening center bichat hospital mondor hospital outpatient consult internal medicine saint louis hospital sickle cell disease inherited red blood cells genetic disorder coordinating referral center henri mondor hospital initial consult screened eligibility standard care sampling sars cov rt pcr nasal saliva antigen test upon positive laboratory confirmation covid information eligible participate randomly assigned one following treatment arm camostat mesylate milligrams milligrams arm placebo tablet blinded arm visit follow visit performed day follow visit include medical interview either person teleconsultation paramedical assessment registered nurse vital sign measurement biological sampling included benefit standard care ambulatory monitoring covid biological monitoring blood sampling serum electrolyte creatinine liver enzyme virological monitoring rt pcr nasal swab day performed locally following standard practice care data collected via web based standardized electronic case report form case hospitalization hospital report used source data collection general practitioner randomization performed centrally via web based system ensure allocation concealment use pre specified randomization list based permutation block planned current knowledge sars cov infection adult expect roughly newly diagnosed high hospitalized within day design initially included planned interim analysis one third observation completed maximum sample size evaluable per group would allow power detect absolute difference probability hospitalization day group reduction using test one sided significance level efficacy using lan demets spending function obrien fleming boundary approximation efficacy futility stopping rule overall group would included anticipate potential drop rate given ambulatory follow however due status pandemic fall global use vaccine scientific comittee decided stop recruitment eventually discontinue early planned interim sample size reached eventually single final analysis performed one sided significance level endpoint endpoint analysed planned recruiting center emergency department saint louis hospital paris covid screening center bichat hospital emergency department argenteuil hospital centre de sante richerand paris emergency department mondor hospital creteil outpatient consult infectious disease deparment covid screening center henri mondor hospital creteil outpatient consult sickle cell disease inherited red blood cell genetic disorder coordinating referral center mondor hospital creteil post emergency internal medicine department mondor hospital creteil department infectious tropical disease public health unit groupe hospitalier sud ile de france ghsif melun emergency department lariboisiere hospital paris non recruiting center follow visit internal medicine department argenteuil hospital office doctor amazzough paris office doctor marzouk paris follow day duration recruiting center average given required sample size planned descriptive analysis use either frequency percentage categorical variable median interquartile range quantitative variable number missing value reported endpoint probability hospitalization within day compared group using two sided test endpoint compared across group using fisher exact test comparing probability group wilcoxons rank sum test comparing quantitative endpoint analysis performed intention treat principle two sided significance level used comparison endpoint",
  "RECORDS": "rapid recognition corticosteroid resistant sensitive sepsis estimate yearly million people develop sepsis million die aprocchs placebo controlled demonstrated absolute reduction sepsis mortality hydrocortisone fludrocortisone number factor may positively negatively impact corticosteroid benefit sepsis compare effect hydrocortisone plus fludrocortisone placebo composite death persistent organ dysfunction defined continued dependency mechanical ventilation new renal replacement therapy vasopressor assessed day intensive care unit intensive care unit adult different biological profile immune response corticosteroid bioactivity endpoint death persistent organ dysfunction defined continued dependency mechanical ventilation renal replacement therapy vasopressor sofa score day mortality health related quality life daily organ function sofa score day daily infection day daily blood urinary level glucose sodium potassium day daily gastroduodenal bleeding day daily cognitive function muscle strength day day multi arm parallel blinded randomized controlled preceded run observational observational run interventional old admitted intensive care unit proven suspected infection main diagnosis community acquired pneumonia related sepsis vasopressor dependency norepinephrine epinephrine vasopressin dopamine phenylephrine septic shock singer vasopressor maintain mean blood pressure least mmhg lactate level mmol acute respiratory distress syndrome ards ranieri acute onset within one week apparent insult progression respiratory syndrome bilateral opacity chest imaging explained pulmonary pathology pleural effusion atelectasis nodule etc evidence heart failure volume overload pao fio millimeter hg peep cm signed written whevener able ascent representant whenever present time screening tested one record specific biomarkers circi endocan gilz dusp mdw lymphopenia transcriptomic standard endotype pcr covid pcr influenza pcr respiratory virus cutaneous vasoconstrictor response glucocorticoid affiliation social security system universal health coverage couverture maladie universelle cmu guardianship curatorship included case simple emergency legal definition included managed covid biological sample available pregnancy expected death withdrawal life sustaining treatment within hour previously enrolled formal indication corticosteroid according recent international guideline vaccination live virus within past hypersensitivity hydrocortisone fludrocortisone microsined betamethasone dipropionate excipients summary of product characteristics woman childbearing potential using contraception nursing woman included stratum applicable apply cream infected ulcerated area observational run additional biological sample restrospective part covid telephone follow interventional investigational product placebo administered basis record signature investigational product included hydrocortisone hemisuccinate milligrams one intravenous injection every hour alpha fludrocortisone one tablet per day via nasogastric tube treatment stopped day left intensive care unit whichever occurs first without tapering web based randomization system available eligible randomized ratio corticoseroids matching placebo use permuted block undisclosed variable size stratify randomization site biomarkers enroll adaptative site expected enroll least per enrolling evaluable per arm power detect absolute reduction corresponds relative reduction day follow daily intensive care unit stay telephone follow",
  "ETOLE": "evaluation tomosynthesis characterization management breast tomosynthesis innovative technique developed digital mammography obtaining sectional image breast mammography main disadvantage imaging projection creates overlay eliminates tomosynthesis evaluate birads classification obtained tomosythesis superior classification obtained conventional mammography term specificity non inferior term sensitivity joint analysis true negative false negative rate according birads scale compared histological result follow outcome see gold standard evaluate tomosynthesis synthetic tomography allows better detection certain sign poor prognosis malignant lesion size multicentricity tumour lymph node extension skin pectoral infiltration tomosynthesis synthetic tomography modifies number additional view number additional examination including ultrasound breast magnetic resonance imaging biopsy assess whether tomosynthesis reduces necessary number ultrasound compare difference rating birads obtained tomosynthesis synthetic mammography ultrasound difference obtained conventional mammography alone combined ultrasound tomosynthesis synthetic mammography change radiation dose received tomosynthesis synthetic mammography improves reproducibility birads classification abnormality cost analysis tomosynthesis synthetic mammography compared mammography mammography ultrasound randomized multi centric iii diagnostic according classification gluud gluud tomosynthesis system installed site manufacturer breast imaging abnormally site given randomized either conventional mammography tomosynthesis incidence synthetic mammography woman breast imaging abnormality breast imaging abnormality classified birads table old signed high breast cancer mutation brca carrier li fraumeni history thoracic radiation excluded greater sensitivity ionizing radiation unable give physical mental legal reason affiliated french social security insurance breast cancer mammography recommended according good practice french health authority pregnant evaluation tomosynthesis characterization management breast conventional digital mammography conventional digital mammography tomosynthesis referred abnormality breast imaging center agreeing participate randomized conventional digital mammography arm atomosynthesis armwith synthetic mammography randomization balanced group stratified center pregnant high breast cancer followed breast cancer may included subject center saint louis hospital tenon hospital lariboisiere hospital hegp duration subject duration saint louis hospital tenon hospital lariboisiere hospital hegp analysis comparison birads classification obtained mammography tomosynthesis rely construction simultaneous confidence interval ratio true negative rate specificity false negative rate sensitivity obtained technics mammography tomosynthesis arm described alonzo others",
  "TEOREM": "multicenter randomized double blind assessing benefit adherent invasive coli eradication adult ileal ileo colonic crohn disease current medical crohn disease cd consists immunosuppressive drug therapy corticosteroid azathioprine methotrexate anti tnf monoclonal antibody agent control symptom cd withdrawal lead disease relapse also associated serious side effect infection lymphoma cancer liver toxicity anti tnf monoclonal antibody efficient cost prohibitive moreover roughly responder anti tnf become refractory often become tolerized drug future cd drug small molecule biologics antagonize pro inflammatory cytokine gut homing lymphocyte yet similar safety issue immunosuppressive agent currently use current therapeutic algorithm cd take account site inflammation composition intestinal microbiota moreover dysregulated intestinal immunity overproduction pro inflammatory cytokine component cd pathophysiology intestinal microbiota abnormal play important role pathogenesis cd coli specie adhesive invasive property adherent invasive coli aiec described ileal mucosa cd aiec found ileal cd control role aiec cd thoroughly investigated several laboratory around world shown aiec pro inflammatory could play important role intestinal inflammation associated cd may important therapeutic target randomized proposes novel approach cd individualized colonized aiec prescribed fda approved antibiotic shown active bacteria vitro discontinued week hope obtain endoscopic remission randomized experimental arm successful first kind facilitate new era research cd concomitant infection aiec objective assess whether week ciprofloxacin rifaximin superior placebo obtain endoscopic remission aiec colonized ileal cd without involvement caecum right colon endpoint overall response week using centralized anonymous blinded reading ileocolonoscopies overall response defined segmental response least one segment cdeis baseline increase cdeis segment cdeis segment segmental response segment cdeis baseline defined case isolated aphtoid ileitis colitis decrease lesion otherwise either decrease surface ulceration either deep superficial loss deep ulceration present increase superficial ulcerated surface objective test correlation endoscopic remission aiec eradication week assess evolution endoscopic lesion week assess rate remission without steroid anti tnf surgery week whose aiec eradicated reached endpoint assess rate biological remission assess side effect experimental placebo group endpoint endoscopic remission week assessed centralized reading ileocolonoscopies defined cdeis segment mean variation segmental cdeis week centralized reading ileocolonoscopies complete endoscopic remission week centralized reading ileocolonoscopies defined cdeis segment ulceration week remission defined cdai without steroid anti tnf resection surgery cd week biological remission defined c reactive protein serum level milligrams fecal calprotectin week side effect ii multicentre prospective randomized double blind placebo controlled adaptive two parallel arm experimental arm oral ciprofloxacin milligrams twice a day oral rifaximin milligrams twice a day week control arm placebo ciprofloxacin twice a day placebo rifaximin twice a day week cd adult infected aiec age cd ileum without involvement caecum right colon severe lesion confined within ileum right colon defined segmental cdeis ileum right colon segmental cdeis segment transverse left colon rectum participate cd either clinically inactive active severe cdai clinically active disease cdai prescription steroid treatment budesonide prednisone prednisolone independently entry note without previous surgery cd without cd anal lesion without draining fistula seton enrolled clinically active disease cdai respond budesonide initial dose milligrams prednisone prednisolone initial dose milligrams point decrease cdai pre visit clinically inactive disease cdai colonized aiec initial ileal biopsy ileal stenosis cannot crossed endoscope methotrexate azathioprine infliximab adalimumab initiated less three preinclusion vedolizumab ustekinumab initiated less six preinclusion discontinuation dosage modification methotrexate azathioprine infliximab adalimumab vedolizumab ustekinumab less three preinclusion hypersensitivity ciprofloxacin quinolones excipients cellulose microcrystalline crospovidone maize starch magnesium stearate silica colloidal anhydrous hypromellose titanium dioxide macrogol tizanidine probenecid theophylline xanthine derivative phenytoin oral anticoagulant ropinirole hypersensitivity rifaximin excipients sodium starch glycolate type glycerol distearate colloidal anhydrous silica talc microcrystalline cellulose hypromellose titanium dioxide disodium edentate propylene glycol red iron oxide previous extensive ileal surgery meter measured pathology surgical report short bowel syndrome need intestinal resection fistula abscess intestinal obstruction renal failure creatinine clearance ml min liver failure factor past history epilepsy aortic aneurysm dissection atherosclerosis hypertension one pathology congenital pre existing disease cardiac valve connective tissue disorder marfan syndrome ehlers danlos syndrome turner syndrome behcets disease rheumatoid arthritis infectious endocarditis health insurance pregnant lactating woman refusal double effective contraception ie hormonal barrier method intrauterine device barrier method double barrier method highly effective method contraception hormonal contraceptive combined oral contraceptive patch vaginal ring injectables implant intrauterine device intrauterine device intrauterine system ius vasectomy tubal ligation effective method barrier method contraception male condom female condom cervical cap diaphragm contraceptive sponge already included biomedical research observational registry cohort association two antibiotic oral ciprofloxacin tablet milligrams every hour week oral rifaximin tablet milligrams milligrams every hour week association two placebo placebo corresponding antibiotic manufactured tablet appearance administrated every hour week ciprofloxacin rifaximin placebo additional biopsy including biopsy ileum right colon aiec search biological collection biopsy rectum aiec search st ileocolonoscopy ileocolonoscopy week including additional biopsy fecal microbiota using pcr screening fecal aiec lpf cd screened realize biopsy check infection aiec bacteria evaluable anticipated infected bacterium responding eligibility criterion included randomized experimental arm rifaximin ciprofloxacin control double placebo arm ileocolonoscopy biopsy made week research aiec infection thereby assess eradication bacteria taking drug placebo bacterial infection also sought stool sample screened needed average obtain randomized pre maximum duration follow duration data analyzed intent treat basis based upon adaptive scheme allowing estimation required number included sample size estimation ssr design taking account uncertainty endoscopic remission rate week placebo arm thus one interim unblind statistical analysis performed successively enrolled endpoint analysis concern comparison main end point ie percentage endoscopic remission group compared using chi square test unless validity violated fisher exact used endpoint analyzed whole sample size reached",
  "UVB:": "multicenter randomized prospective comparing efficacy safety adalimumab tocilizumab severe uveitis behcets disease uvb first randomized prospective head head comparing adalimumab tocilizumab sight threatening uveitis bd anti tnf used bd uveitis incidence blindness bd dramatically reduced recent use biologics firm evidence randomized controlled trial directly addressing best induction therapy severe bd uveitis bd uveitis considered devastating inflammatory ocular disease visual loss reach bilateral involvement contrasting immunosuppressor interferon alpha biotherapies act rapidly highly effective steroid sparing thus preventing occurrence cataract glaucoma however anti tnf failed demonstrate sustainable complete remission severe sight threatening uveitis little published information use biologics anti tnf severe bd uveitis tocilizumab used success severe resistant case one promising biologics bd il expression correlate bd activity immunological data provide strong rationale targeting bd tocilizumab despite strong rationale compound yet approved bd guarantee innovative nature aim selecting dropping arm evidence efficacy already exists assess benefit tocilizumab comparatively adalimumab sight threatening behcets disease uveitis week endpoint efficacy defined complete remission ocular involvement complete resolution retinal vasculitis macular edema prednisone prednisolone prednisone stock market lower equal milligrams day week randomization estimate compare change best corrected visual acuity best corrected visual acuity time complete remission week evaluate compare safety adalimumab tocilizumab evaluate compare change macular edema evaluate compare change sign ocular inflammation evaluate compare effect retinal vessel leakage evaluate compare effect adalimumab tocilizumab steroid sparing evaluate compare change ocular inflammation anterior chamber evaluate compare number time relapse uveitis characteristic uveitis worsening evaluate compare time failure considered failure following criterion met least eye new active inflammatory retinal vascular lesion macular edema worsening best corrected visual acuity best corrected visual acuity line step increase anterior chamber ac cell grade step increase vitreous haze vh grade relative baseline estimate compare effect extra ophthalmologic manifestation behcets disease estimate compare mean change sf quality life behcets disease quality life measure bd quality of life estimate compare change behcets disease current activity form bdca behcets syndrome activity score bsas endpoint measure corticosteroid sparing percent meeting target lower milligrams day kilograms prednisone prednisolone prednisone stock market mean dose week cumulative dose time response onset measure acute reactant erythrocyte sedimentation rate esr reactive protein c reactive protein week rate time occurrence relapse worsening relapse defined reappearance paraclinical feature active disease occurrence new lesion progression preexisting lesion change behcets disease current activity form bdca week change behcets syndrome activity score bsas week change organ involved bd week change quality life quality of life sf tm health survey behcets disease quality life measure bd quality of life week safety tolerability treatment bd assessed frequency severity adverse event week time failure time occurence change tyndall flare vitreous haze week change best corrected visual acuity snellen score week change central retinal thickness measured optical coherence tomography optical coherence tomography week percentage central retinal thickness micron week percentage without retinal vessel leakage retinal angiography week week case retinal vasculitis bayesian design ii randomized aim comparing new reference based binary end point offer greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trial adult sight threatening behcets disease associated uveitis age provide written prior performance specific procedure diagnosis behcets disease according international criterion behcet disease icbd see appendix history aphtosis diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criterion standardization uveitis nomenclature standardization of uveitis nomenclature criterion posterior pan uveitis sight threatening uveitis defined according validated international definition line drop visual acuity scale retinal inflammation macular oedema retinal vasculitis chest ray postero anterior lateral ct scanner result within week prior evidence active tuberculosis active infection malignancy female subject childbearing potential premenopausal female capable becoming pregnant negative serum pregnancy test plasmatic urinary subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner becoming pregnant stopping therapy tocilizumab adalimumab respectively birth control method may considered highly effective method achieve failure rate less per used consistently correctly considered highly effective birth control method according ctfg recommendation method include female subject combined estrogen progestogen containing hormonal contraception associated inhibition ovulation oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire associated treatment reliability sexual abstinence need evaluated relation duration preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence negative tuberculosis test obtained within week prior potential subject positive interferon gamma release assay igra quantiferon tuberculosis gold spot tuberculosis test eligible chest ray show evidence suggestive active tuberculosis disease sign symptom pulmonary extra pulmonary tuberculosis disease subject latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course started latest affiliation social security system affiliated universal medical coverage cmu eligible infectious uveitis masquerade syndrome uveitis due cause bd uveitis active tuberculosis history untreated tuberculosis severe infection positive human immunodeficiency virus antibody positive hepatitis surface antigen positive hepatitis rna result obtained within prior history malignancy within prior carcinoma situ cervix non metastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody history multiple sclerosis demyelinating disorder hypersensitivity active substance excipient investigational medicinal product auxiliary medicine active suspected ocular infection active suspected systemic infection history intestinal ulceration diverticulitis known porphyria laboratory value assessed neutrophil millimeter platelet count millimeter aspartate amino transferase alanine-aminotransferase upper limit of normal anti tnf tocilizumab therapy within prior azathioprine mycophenolate mofetil methotrexate time drug must withdrawn prior receiving tocilizumab adalimumab dose day stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency severe renal glomerular filtration rate gfr ml min liver insufficiency prothrombin without cause live attenuated vaccine within day prior breastfeeding pregnant woman collection free eligible sight threatening behcets disease uveitis randomized one group randomization visit arm adalimumab milligrams milligrams subcutaneous week arm tocilizumab milligrams subcutaneous week week applicable visit internist week visit ophthalmologist week hcg urinary visit monthly stopping therapy tocilizumab adalimumab respectively optical coherence tomography optical coherence tomography retinal angiography case retinal vasculitis quality of life questionnaire week bd uveitis considered devastating inflammatory ocular disease anti tnf rapidly acting agent compared methylprednisolone interferon alpha suppressing ocular inflammation however failed demonstrate sustainable complete remission also tnfa antagonist seems suspensive effect ocular inflammation bd tocilizumab used success severe resistant case one promising biologics bd rapid onset action steroid sparing effect characterize efficacy tocilizumab nowadays management severe bd still remains largely empirical first randomized head head therapeutic management severe uveitis bd biologics may assess benefit tocilizumab comparatively adalimumab sight threatening behcets disease term safety efficacy steroid sparing could thus improve care bd uveitis general expected benefit individual reducing morbidity rate blindness young bd collective reducing cost hospitalization dependence associated toxicity investigational drug associated use contrast medium retinal angiography level collection free eligible active sight threatening behcets disease uveitis randomized one group randomization visit arm adalimumab milligrams milligrams subcutaneously week arm tocilizumab milligrams subcutaneously every week week group receive corticosteroid regimen receive oral prednisone prednisolone prednisone stock market milligrams kilograms day milligrams day randomization following schedule reduction prednisone prednisolone prednisone stock market apply group long disease inactive milligrams kilograms day maximum milligrams week milligrams day milligrams day milligrams day milligrams day milligrams day milligrams day dose corticosteroid left investigator discretion arm multicenter national including center follow duration experimental design open multicenter randomized stratified characteristic initial uveitis behcets disease retinal inflammation retinal vascularitis macular edema according diagnosis newly diagnosed relapsing disease evaluation assessment criterion week assessment criterion reviewed scientific committee blinded randomization rct use bayesian design ii randomized national multicenter aim comparing new reference based binary endpoint complete remission week offer greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trial use beta binomial model non informative prior berry posterior probability remission rate least estimated arm probability rate remission arm arm computed indicating tocilizumab group adalimumab group use bayesian inference framework denotes probability remission arm na arm ya complete remission observed using beta prior posterior probability still beta distribution given due natural conjugate property beta family binomial sampling setting efficacy drug arm first assessed comparison historical minimal value interest sometimes called minimum required remission rate set thus compute similar analysis performed arm however randomized ii setting selection new drug mostly based evaluating potential benefit experimental treatment thus one may consider dropping new drug rather low posterior probability drug beneficial targeted minimal level done computing posterior probability difference remission rate two experimental arm kawasaki greater zero tocilizumab group adalimumab group consider bayesian design interim analysis performed without alpha spending stopped corresponding arm stopped following included arm stopped",
  "RUBI": "multicenter randomized multi arm comparing efficacy safety adalimumab anakinra tocilizumab subject non infectious refractory uveitis rubi first prospective randomized head head comparing adalimumab either anakinra tocilizumab refractory neutrophil immune unit firm evidence randomized controlled trial directly addressing best biologic agent severe refractory neutrophil immune unit neutrophil immune unit cause devastating visual loss legal blindness corticosteroid immunosuppressant failed demonstrate sustainable remission refractory relapsing severe uveitis incidence blindness neutrophil immune unit dramatically reduced recent use biologics raising question whether compound used earlier severe non infectious uveitis contrasting immunosuppressor biotherapies act rapidly highly effective steroid sparing thus preventing occurrence cataract glaucoma despite strong rationale compound yet approved uveitis guarantee innovative nature aim selecting dropping arm evidence efficacy already exists objective evaluate efficacy adalimumab milligrams milligrams day compared anakinra milligrams day tocilizumab milligrams day subject refractory non infectious intermediate posterior pan uveitis neutrophil immune unit prednisone dose milligrams kilograms day prednisone equivalent oral corticosteroid week endpoint efficacy measured percentage least step reduction vitreous haze according miami step scale dose milligrams kilograms day prednisone equivalent oral corticosteroid objective evaluate change best corrected visual acuity best corrected visual acuity evaluate safety adalimumab anakinra tocilizumab neutrophil immune unit evaluate change macular edema evaluate change sign ocular inflammation evaluate effect retinal vessel leakage evaluate effect adalimumab anakinra tocilizumab steroid sparing evaluate change ocular inflammation anterior chamber evaluate effect underlying systemic disease appropriate evaluate effect ocular disease evaluate number time relapse uveitis characteristic uveitis worsening evaluate time failure endpoint measured week best corrected visual acuity best corrected visual acuity change macular edema change sign ocular inflammation retinal vessel leakage steroid sparing ocular inflammation anterior chamber underlying systemic disease appropriate ocular disease number time relapse uveitis characteristic uveitis worsening adverse event time failure prospective ii multicenter multi arm randomized comparing efficacy safety adalimumab anakinra tocilizumab subject active refractory non infectious intermediate posterior pan uveitis oral corticosteroid stable dose day prior first drug administration day systemic immunosuppressant must discontinued day prior first drug administration day access oral corticosteroid needed day adult active refractory non infectious uveitis neutrophil immune unit active disease either presence vh miami step scale macular edema crt micron sign intraocular inflammation eg perivascular sheathing retinal vessel leakage retinal vessel fa recently active disease evidence activity within prior visit per vh miami step scale vh according standardization of uveitis nomenclature classification macular edema crt micron sign intraocular inflammation perivascular sheathing retinal vessel leakage retinal vessel fa activity status active disease recently active disease confirmed randomization reading center evaluation vh optical coherence tomography fa assessment refractory disease subject must receiving oral corticosteroid milligrams day prednisone equivalent milligrams day least one immunosuppressive azathioprine methotrexate mycophenolate mofetyl cyclosporine leflunomide cyclophosphamide interferon ifn intolerant immunosuppressive therapy eligibility criterion checked selection visit take place four week maximum prior visit randomization visit adult meeting following criterion may included provide written prior performance specific procedure diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criterion standardization uveitis nomenclature standardization of uveitis nomenclature criterion posterior pan uveitis confirmed documented medical history currently uncontrolled uveitic disease uncontrolled uveitic disease defined fulfilling two following criterion within week prior active inflammatory chorioretinal inflammatory retinal vascular lesion macular edema crt micron vitreous haze grade miami step scale vh according standardization of uveitis nomenclature national eye institute classification receiving prednisone milligrams day milligrams day equivalent dose another corticosteroid stable dose day prior first drug administration day received least systemic immunosuppressant systemic immunosuppressant must discontinued day prior first drug administration day received ifn systemic immunosuppressant must discontinued day prior first drug administration day intolerant immunosuppressant best corrected visual acuity best corrected visual acuity early treatment diabetic retinopathy study either eye stable dose two week prior topical corticosteroid nsaid male female age weight kilograms lb chest ray thoracic ct scan result postero anterior lateral within week prior evidence active tuberculosis active infection malignancy female subject child bearing age negative serum urine pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner becoming pregnant stopping therapy roactemra adalimumab respectively birth control method may considered highly effective method achieve failure rate less per used consistently correctly considered highly effective birth control method according ctfg recommendation method include combined estrogen progestogen containing hormonal contraception associated inhibition ovulation oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire associated treatment reliability sexual abstinence need evaluated relation duration preferred usual lifestyle subject quantiferon tuberculosis tuberculosis test within prior screening subject included meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permitted isolated anterior uveitis presence cataract posterior capsular opacification severe assessment posterior segment either eye inadequate impossible contraindication mydriasis either eye presence posterior synechiae eye mydriasis inadequate posterior segment examination intraocular pressure mmhg goldmann tonometry advanced glaucoma either eye monocular active tuberculosis known positive syphilis serology human immunodeficiency virus antibody hepatitis surface antigen anti nucleocapsid antibody hepatitis virus hepatitis virus within prior history malignancy within prior carcinoma situ cervix non metastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody infectious disease fever infection requiring antibiotic within week prior history recurrent infection predisposition infection known immunodeficiency history multiple sclerosis demyelinating disorder laboratory value assessed hemoglobin deciliter white blood cell count millimeter platelet count millimeter glomerular filtration rate gfr ml min transaminase time upper normal value use following systemic treatment specified previous systemic biologic therapy systemic alkylating agent within prior day cyclophosphamide chlorambucil live attenuated vaccine within prior use following ocular treatment specified previous anti vegf intravitreal therapy applies eye within prior anticipated use dexamethasone intravitreal implant ozurdex within prior intravitreal corticosteroid within prior previous subtenons corticosteroid injection permitted administered least prior stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency eligible active refractory neutrophil immune unit randomized ratio arm adalimumab milligrams milligrams day subcutaneously week arm anakinra milligrams day subcutaneously week arm tocilizumab milligrams day subcutaneously week three group receive corticosteroid regimen neutrophil immune unit receive oral prednisone milligrams kilograms day maximum milligrams day prednisone equivalence following schedule reduction prednisone apply group long disease inactive milligrams kilograms day prednisone week milligrams kilograms day prednisone week week milligrams kilograms day prednisone week week milligrams kilograms day prednisone week week milligrams kilograms day prednisone week week due csi recommendation anakinra arm stopped investigational medicinal product anakinra discontinued undergoing follow thus modified planned analysis randomisation accordingly randomisation next randomized either remaining arm arm adalimumab milligrams milligrams day subcutaneously week arm tocilizumab milligrams day subcutaneously week practice mean remaining planned randomized arm arm ophthalmologic visit week fluorescein indocyanine green angiogram fa icg week ocular coherence tomography optical coherence tomography week randomization stratified retinal vasculitis macular oedema underlying disease randomization prednisone one eye selected eye eligible per exclusion criterion following rule respected eye active disease selected versus eye recently active disease defined protocol eye present active disease documented unique parameter eye worse score selected eye present active disease defined several parameter eye worse score ranked follows selected vitreous haze cystoid macular edema cme retinal vascular leakage best corrected visual acuity best corrected visual acuity eye equivalent score right eye selected receive ocular coherence tomography optical coherence tomography enrolment fluorescein indocyanine green angiogram fa icg enrolment visit case vasculitis worsening department french public hospital duration duration maximum duration centre use bayesian multi arm multi stage mam design aim comparing several new treatment multi arm order select drop arm move forward evidence already exists based interim analysis randomization stratified retinal vasculitis macular oedema underlying disease randomization prednisone single therapy",
  "ITAC": "multicenter randomized prospective comparing efficacy safety infliximab cyclophosphamide severe behcets disease itac first randomized prospective head head comparing infliximab cyclophophamide severe manifestation bd behcets disease bd systemic vasculitis arterial venous vessel size involving young bd significantly increase morbidity mortality therape utic management bd depends presentation organ involved although colchicine nonsteroidal antiinflammatory agent topical treatment often sufficient mucocutaneous joint involvement aggressive approach immunosuppressive agent warranted severe manifestation retinal vasculitis cardio vascular neurological involvement early recognition vigorous use immunosuppressive high dose steroid changed prognosis severe bd bd severe systemic vasculitis leading mortality rate major vessel neurological involvement cyclophosphamide used life threatening bd however outcome severe complication bd still poor european league rheumatism european league against rheumatism recommendation updated management bd advocated cyclophosphamide anti tnf plus glucocorticoid life threatening manifestation neurological major vessel involvement recommendation vascular disease neurological involvement based largely expert opinion uncontrolled evidence open trial observational need properly designed controlled trial apparent tnfa antagonist used success severe resistant case addition incidence blindness bd dramatically reduced recent use anti tnf however firm evidence randomized controlled trial directly addressing best induction immunosuppressive therapy severe bd manifestation physician still prescribing compound label use therefore aimed assess best induction therapy severe difficult treat bd assess benefit infliximab comparatively cyclophosphamide severe life threatening behcets disease assessment criterion complete response week randomization estimate compare rate time occurrence relapse worsening estimate compare cumulative dose steroid estimate compare adverse event estimate compare mean change sf quality life see appendix estimate compare rate remission according organ involved compare change acute reactant estimate compare change central nervous system involvement estimate compare change cardio vascular involvement survival event free survival estimate compare change bd manifestation estimate compare change behcets disease current activity form see appendix assess serum concentration measurement tnfa inhibitor endpoint complete response week remission central nervous system cardiovascular involvement week measure corticosteroid sparing percent meeting target milligrams day kilograms prednisone week mean dose week cumulative dose week time response onset measure acute reactant reactive protein c reactive protein every week relapse time relapse relapse defined reappearance paraclinical feature active disease occurrence new lesion week rate relapse worsening time occurrence worsening worsening defined progression preexisting lesion week rate worsening gobal survival week event free survival week defined occurrence death relapse worsening safety tolerability treatment bd assessed frequency severity adverse event week change quality life quality of life sf tm health survey week see appendix change central nervous system involvement physical exam cerebral medullar magnetic resonance imaging week change vascular involvement physical exam vascular doppler angio ct imaging biologically normalization reactive protein week change cardiological involvement physical exam echocardiography normalization left ventricular function disappearance cardiac thrombosis cardiac magnetic resonance imaging diseappearance gadolinium enhancement normalization left ventricular function biologically normalization troponin reactive protein week change organ involved bd serum concentration measurement tnfa inhibitor week change behcets disease current activity form see appendix week bayesian design ii randomized aim comparing new reference based binary end point offer greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trial adult pediatric severe life threatening behcets disease age old written inform obtained legal guardian accordance regional law regulation age diagnosis bd according international criterion bd icbd see appendix life threatening active bd defined following disease category according validated international definition major vessel disease arterial aneurysm arterial stenosis myocarditis major deep vein thrombosis inferior vena cava superior vena cava cardiac cavity thrombosis pulmonary embolism supra hepatic vessel renal mesenteric vessel diagnosis major vessel involvement done using vascular doppler sonography echocardiography angio ct scan cardiac magnetic resonance imaging magnetic resonance imaging central nervous system involvement encephalitis meningoencephalitis myelitis diagnosis neuro behcets central nervous system involvement based objective neurological symptom associated neuroimaging central nervous system medullar magnetic resonance imaging finding suggestive bd related central nervous system involvement cerebrospinal fluid cerebro spinal fluid finding showing aseptic inflammation may associated chest ray result postero anterior lateral within week prior evidence active tuberculosis active infection malignancy female subject child bearing age negative pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner becoming pregnant stopping therapy adequate contraceptive measure include hormonal method used two cycle prior oral contraceptive pill contraceptive patch contraceptive vaginal ring barrier method contraceptive sponge diaphragm used conjunction contraceptive foam jelly condom used conjunction contraceptive foam jelly intrauterine method intrauterine device sterilization tubal ligation monogamous relationship vasectomized partner abstinence potential subject positive interferon gamma release assay igra quantiferon tuberculosis gold spot tuberculosis test positive tuberculin skin test eligible chest ray show evidence suggestive active tuberculosis disease sign symptom pulmonary extra pulmonary tuberculosis disease subject latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course human immunodeficiency virus negative serology negative hb ag test subject included meet following criterion evidence active tuberculosis human immunodeficiency virus active hbv infection hb ag pregnancy lactation taking oral daily dose glucocorticoid milligrams prednisone equivalent week continuously prior visit taking milligrams methylprednisolone week prior visit alcohol drug dependance severe renal creatinine clairance ml min pre existing hemorrhagic cystitis liver insufficiency hepatic encephalopathy urinary obstruction heart failure stage iii intravenous infusion “new york heart association” history malignancy within prior carcinoma situ cervix excised basal cell squamous cell carcinoma skin history multiple sclerosis demyelinating disorder history severe allergic anaphylactic reaction cyclophosphamide infliximab infectious disease infection requiring intravenous antibiotic within week prior history recurrent infection laboratory value assessed hemoglobin deciliter white blood cell count millimeter platelet count millimeter use following systemic treatment specified systemic biologic therapy cyclophosphamide within prior azathioprine mycophenolate mofetil methotrexate time drug must withdrawn prior receiving cyclophosphamide infliximab dose day live attenuated vaccine within week prior recombinant killed virus vaccine permitted lack affiliation social security benefit plan beneficiary assignee affiliated universal medical coverage cmu eligible infliximab milligrams kilograms intravenously week cyclophosphamide intravenously week evaluation serum concentration anti tnf week intermediate collection free eligible active behcets disease randomized one group randomization visit arm infliximab milligrams kilograms intravenously week arm cyclophosphamide intravenously week receive corticosteroid regimen randomisation visit oral prednisone milligrams kilograms day milligrams day following schedule reduction prednisone apply group long disease inactive week milligrams kilograms day week milligrams kilograms day week milligrams kilograms day week milligrams kilograms day week milligrams kilograms day week milligrams kilograms day week milligrams kilograms day week milligrams kilograms day arm multicentre national including centre duration duration duration centre experimental design multicentric open multicenter randomized stratified characteristic initial behcets disease evaluation assessment criterion week assessment criterion final measure corticosteroid sparing reviewed scientific committee blinded randomization rct use bayesian design ii randomized national multicentre aim comparing new reference based binary endpoint complete response week offer greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trial",
  "SHORTCUT": "efficacy day versus day antibiotic therapy acute pyelonephritis kidney transplant recipient multicentre randomized non inferiority infection major cause morbidity mortality solid organ transplant recipient kidney transplant recipient ktr urinary tract infection uti represent infection hospitalization sepsis acute transplant pyelonephritis common complication occurring mainly first transplantation associated increased acute kidney rejection long term kidney graft dysfunction gram negative bacteria mainly coli account uti ktr infection favored urinary tract modification defect immunosuppression often recurrent necessitate repeated course antibiotic selective pressure due antibiotic consumption along frequent hospital admission immunosuppression well known factor development antibiotic resistant infection multidrug mdr extensively xdr drug resistant enterobacteriaceae including esbl carbapenemase producing organism thus increasingly observed transplant unit represent global threat new antibiotic expected next decade one main strategy limit antimicrobial resistance reduce duration antibiotic day course recommended simple acute pyelonephritis apn treated fluoroquinolones parenteral lactams prolonged day presence underlying disease complication kt team treat day recommended american guideline however need extend duration immunosuppressed poorly defined concept optimal duration apn ktr known excluded urgent need reduce antibiotic consumption population high developing infection due resistant pathogen hypothesis day sufficient cure apn good response ktr effective day show day antibiotic therapy inferior day antibiotic therapy acute pyelonephritis kidney transplant recipient endpoint cure additional antibiotic since end antibiotic main evaluation day cure defined fever symptom uti compare arm cure day day microbiological cure day tolerance safety antibiotic hospitalization length stay antibiotic consumption follow acquisition antibiotic resistant enterobacteriaceae kidney graft function transplant rejection day day cost evaluate factor failure relapse recurrence evaluate efficacy antibiotic end experimental arm control group endpoint cure day microbiological cure day incidence relapse recurrence day day incidence adverse event imputable antibiotic kidney function assessed according mdrd modification diet renal disease ckd chronic kidney disease epidemiology collaboration epi hospitalization length stay defined delay date date hospital discharge antibiotic consumption rectal carriage antibiotic resistant enterobacteriaceae day microbiological cure defined sterile urine uropathogene cfu ml urine culture multicenter controlled randomized non inferiority open label parallel group day versus day antibiotic randomization stratified date renal transplantation center sex potential confounders ktr acute pyelonephritis age ktr apn defined fever without sign symptom uti pyuria white blood cell ml millimeter positive urine culture uropathogen cfu ml susceptible empirically administrated antibiotic confirmed suspected febrile non urinary bacterial infection urologic renal complication baseline imaging abscess obstruction favourable early response antibiotic hour first dose antibiotic effective causative uropathogen defined improvement resolution sign symptom urinary tract infection present diagnosis written following condition severe complicated condition rapidly progressing disease immediately life threatening illness including limited septic shock current impeding respiratory failure acute heart liver failure admission stay intensive care unit baseline obstruction urinary tract renal perinephric prostatic abscess prior current another interventional dual antibiotic therapy prophylactic antibiotic cotrimoxazole allowed dose aminoside allowed randomization first post transplantation current indwelling catheter including bladder catheter ureteral stent percutaneous nephrostomy tube neurogenic bladder enterocystoplasty immunodeficiency immunosuppressive therapy related kidney transplantation including hematologic malignancy cancer asplenia neutropenia neutrophil millimeter pregnancy breastfeeding hypersensitivity previous severe adverse drug reaction antibiotic therapy unable unwilling judgment investigator comply protocol life expectancy legal guardianship without healthcare coverage homeless woman childbearing potential using adequate contraception standard day antibiotic duration swab bacterial resistance rectal carriage follow consultation added standard procedure uti could relapse frequently short duration arm non inferiority demonstrated require new antibiotic intravenous infusion length length duration sample size group achieve power detect non inferiority margin difference group proportion reference group proportion group proportion assumed null hypothesis inferiority power computed case actual group proportion test statistic used one sided test unpooled significance level test",
  "CAALL": "caall french protocol acute lymphoblastic leukemia child adolescent curable disease child adolescent nevertheless numerous problem remain good result obtained intensive prolonged treatment include toxic death sequela malignancy result still insufficient high form particularly exhibiting early resistance chemotherapy early bone marrow relapse less diagnosis still dismal prognosis render prevention mandatory extremely heterogeneous disease term biology response envisage targeted treatment future render key decipher heterogeneity two cooperative group fralle french center eortc clcg decided elaborate common protocol childhood adolescent childhood adolescent france caall two previous group comparable result still major question field optimal use asparaginase asnase known administering asnase result depletion asparagine circulating blood starves leukemic cell result death indeed use asnase varies protocol considering different brand dose administration modality rythm route intramuscular intravenous infusion three major form asnase currently available coli asparaginase kidrolase france erwinia asparaginase erwinase allergy pegylated form coli asparaginase oncaspar usa europe oncasparin usa oncaspar pegylated coli asparaginase pegaspargase manufactured initially enzon shire servier developed goal reducing immunogenicity native asnase addition oncaspar prolonged serum terminal half life dosed less frequently native asnase achievement similar pharmacodynamic usa ccg pivotal supporting first line use oncaspar child standard randomized receive native pegylated coli asparaginase active pharmaceutical ingredient merck part induction delayed intensification di oncaspar administered intramuscularly intramuscular dose iu week induction two week di native coli asparaginase merck elspar administered intramuscular dose iu three time weekly dos induction dos di child treated oncaspar rapid clearance lymphoblast day day bone marrow aspirate prolonged asparaginase activity treated native form first di native asparaginase high titer antibody compared receiving oncaspar high titer antibody associated low asparaginase activity native arm oncaspar arm rate infection hospitalization safety profile similar arm avramis others oncaspar approved component multi agent chemotherapy usa since including first line use since first line use transferred new oncaspar manufactured sigma tau pegaspargase asparaginase lonza shire oncaspar europe oncaspar currently available europe differed oncaspar marketed usa term asparaginase origin kyowa hakko lonza although product pegylated sigma tau usa germany poland oncaspar kh kyowa hakko registered component antineoplastic combination therapy reinduction known hypersensitivity native asparaginase second line oncaspar kh used first line asparaginase preparation least three european protocol uk mrc protocol since uk bfm aieop protocol since germany italy austria switzerland czech republic israel interfant protocol dedicated infant since many country since january european commission granted marketing authorization use oncaspar combination therapy acute lymphoblastic leukaemia pediatric birth adult approval baxalta authorized market oncaspar member country european union eu well iceland liechtenstein norway authorization related oncaspar incorporating active pharmaceutical ingredient manufactured lonza authorization transferred subsequent owner shire currently servier current status asparaginase preparation france january kidrolase registered first line use erwinase available allergic native pegylated asparaginase maa france oncaspar oncaspar kh available named program atuon november oncaspar received marketing authorization january different dosing schedule using oncaspar induction therapy currently proposed according first line protocol opened date iu one infusion cog dfci protocol using oncaspar lonza iu one infusion st jude protocol oncaspar lonza iu two infusion aieop bfm protocol europe oncaspar kh iu two infusion eortc protocol belgium oncaspar kh iu one infusion interfant protocol mainly europe oncaspar kh iu two infusion ukall protocol uk oncaspar kh iu two infusion dcog protocol nl oncaspar kh result protocol ukall interesting event-free survival overall survival vora others lancet oncol obtained using low dosage per infusion oncaspar kh iu intramuscular repeated day interval induction subgroup treated ukall cyk fong others ash show dose provides adequate asparaginase activity iu sample studied st second injection french protocol first europe use oncaspar lonza used usa since first approval another oncaspar manufactured merck active pharmaceutical ingredient randomized question best way administer pegaspargase cohort child adolescent standard medium randomized receive induction either one infusion oncaspar lonza iu two infusion oncaspar lonza iu receive iu iu per dose consolidation delayed intensification according initial arm randomization non randomized question high high group non randomized intensification scheme asparaginase administration proposed induction therapy infusion iu day administered receive iu per dose consolidation delayed intensification child adolescent standard medium two objective assess superiority term pharmacokinetic fractionated scheme assess equivalence tolerance scheme induction high high group two objective defined assess pharmacokinetic assess toxicity intensified scheme induction adequate asparaginase activity iu induction toxicity incidence severe toxicity grade directly asparaginase related central nervous system thrombosis pancreatitis anaphylaxia hyperbilirubinemia anyway consolidation linked drug pharmacokinetics pharmacodynamics immunogenicity comparison arm made standard medium non comparative assessment made belonging high high group criterion include asparaginase activity asparagine level defined time point incidence asparaginase antibody incidence silent inactivation arm induction consolidation intensification allergic reaction rate arm induction consolidation intensification percentage without switch erwinia asparaginase percentage receiving intended dose asparaginase efficacy comparison arm made standard medium non comparative assessment made belonging high high group criterion efficacy include morphological complete remission rate assessed whole population subgroup lineage cell minimal residual disease minimal residual disease end induction time point later time point time point time point subgroup assessed ig tcr based rq pcr evaluation made whole population within subgroup cumulative incidence relapse cumulative incidence bone marrow relapse central nervous system relapse gonadal relapse combined relapse toxicity comparison arm undertaken standard medium non comparative assessment made belonging high high group adverse event adverse event related asparaginase occurring within first week anyway consolidation hyperglycemia induced diabetes coagulopathy allergy hyperlipidemia hypertriglyceridemia hypercholesterolemia non central nervous system thrombosis grade adverse event pancreatitis hyperbilirubinemia adverse event related asparaginase occurring induction anyway consolidation incidence grade adverse event whatever imputability survival time point event free survival disease free survival overall survival classical outcome measure evaluation survival child event free survival survival time free failure relapse malignancy day randomization randomized arm disease free survival event free survival responder measured time complete remission following induction failure defined induction day day least blast minimal residual disease case available minimal residual disease blast criterion required objective evaluate incidence rare subgroup prognostic value called subgroup bcr abl like including ebf pdgfrb mef znf tcf hlf event-free survival disease-free survival rare suboptimal response therapy induction failure mrdtp abl class fusion alls treated imatinib imatinib related adverse event immediate long term cf appendix rare suboptimal response therapy induction failure mrdtp abl class fusion alls treated imatinib national cancer institute standard criterion cell precursor day age white blood cell count national cancer institute high cell precursor age white blood cell count cell cell lineage central nervous system involvement central nervous system status according current standard definition central nervous system central nervous system central nervous system traumatic lumbar puncture traumatic lumbar punction testis involvement enlargement one testis confirmed ultrasonography prednisone response measured induction therapy good prednisone response gpr less blast cell millimeter day prednisone milligrams day one intrathecal injection methotrexate poor prednisone response ppr good prednisone response minimal residual disease minimal residual disease measured induction consolidation evaluation real time quantitative pcr search two ig tcr marker possible least one minimum sensitivity according esg minimal residual disease recommendation detectable minimal residual disease mean signal least one marker sensitivity level case failure less case flow cytometry evaluation minimal residual disease done reference centre cell precursor subgroup pretreated corticosteroid refer protocol table section standard standard national cancer institute standard central nervous system gonadal involvement hypodiploidy chromosome monosomy tcf hlf tcf pbx iamp mll rearrangement good prednisone response randomized question pegaspargase iu one infusion induction consolidation delayed intensification pegaspargase infusion iu induction infusion iu consolidation delayed intensification medium medium national cancer institute standard poor prednisone response national cancer institute high good prednisone response tcf pbx high very high criterion monosomy gonadal involvement high very high criterion mll rearrangement iamp hypodiploidy chromosome dna index tcf hlf central nervous system involvement central nervous system randomized question arm pegaspargase iu one infusion induction consolidation delayed intensification arm pegaspargase infusion iu induction infusion iu consolidation delayed intensification high high high very high pt national cancer institute high poor prednisone response pt least one following feature mll rearrangement hypodiploidy chromosome dna index translocation tcf hlf iamp pt central nervous system status uncontrolled question two infusion pegaspargase iu induction pegaspargase iu consolidation subsequent hematopoietic stem cell transplantation strategy subgroup non responder very high stratification switch occur either induction induction failure assessment ikzf status minimal residual disease time point result later minimal residual disease time point result refer protocol switch table section cell subgroup pretreated corticosteroid refer protocol table section standard standard good prednisone response central nervous system minimal residual disease time point randomized question arm pegaspargase iu one infusion induction delayed intensification arm pegaspargase infusion iu induction infusion iu delayed intensification high high high very high poor prednisone response central nervous system minimal residual disease time point uncontrolled question two infusion pegaspargase iu induction pegaspargase iu consolidation subsequent hematopoietic stem cell transplantation strategy subgroup non responder very high stratification switch occur either induction induction failure minimal residual disease evaluation time point time point subgroup refer protocol switch table section child adolescent age yearsb lineage lineage written obtained day nb syndrome included randomized see detail protocol section burkitts leukemia lmb type protocol mixed phenotype acute leukemia criterion infant age day interfant protocol leukemia previously treated chemotherapy steroid exposed pt included stratified according section known allergy pegylated product pregnancy woman child bearing potential defined woman physiologically capable becoming pregnant must negative serum pregnancy reliable contraception except oral contraceptive contraception maintained throughout discontinuation known human immunodeficiency virus positivity central nervous system thrombosis prophase hydrogen ion concentration bcr abl esphall protocol central nervous system thrombosis french prospective multicentric cohort child adolescent stratified type ii anticipated stratified group bcp group cell randomized performed population composed standard medium standard checking eligibility criterion using two parallel arm randomization design allocated either receive one infusion oncaspar iu infusion iu induction therapy dose per infusion induction therapy dose per infusion attributed initial randomization randomized question asked high high group lineage receiving infusion oncaspar iu induction iu infusion afterwards nevertheless submitted evaluation term pharmacokinetic pharmacodynamic toxicity efficacy included caall day induction randomization take place day first infusion pegaspargase belonging standard medium standard group oncaspar pegaspargase supplied sterile solution beginning replaced powder solution injection packaged type single use vial containing international unit native asparaginase per ml solution oncaspar stored refrigeration product must shaken frozen must protected light refer protocol morphology blood bone marrow according standard procedure immunophenotyping according standard procedure cytogenetics standard procedure fish tel acute myeloid leukemia detects tel acute myeloid leukemia etv runx translocation iamp confirms indirectly hyperdiploidy fish mll rearrangement molecular cytogenetics genetics lineage tel acute myeloid leukemia etv runx mll af bcr abl tcf pbx hlf lineage dic hypercalcemia ikzf mlpa multiplex pcr cgh satellite biology non mandatory protocol crlf hyperexpression crlf lesion igh crlf ry crlf crlf hydrogen ion concentration like new druggable fusion transcript entity lineage satellite biology non mandatory protocol hox hox sil tal calm af nup abl notch fxbw flash rheumatoid arthritis pten minimal residual disease evaluation real time quantitative pcr search two ig tcr marker possible least one minimum sensitivity according esg minimal residual disease recommendation time point time point time point time point subgroup ig tcr minimal residual disease evaluation minimal residual disease centralized centre lille paris robert debre paris necker paris st louis toulouse rennes case failure less case flow cytometry evaluation minimal residual disease done reference centre asparaginase activity center whole duration asparagine depletion limited number center antibody asparaginase pegaspargase i.e. pegylated asparaginase center first sampling time point refer protocol appendix comprehensive bio banking connected database performed enable subsequent research may include array cgh snp array new technology measure gain loss chromosomal region even subtle necessary assess impact term diagnosis prognosis prospectively induction failure high level minimal residual disease screened necessary technique fish cgh dna rna sequencing search molecular abnormality allowing use targeted drug particularly tyrosine kinase inhibitor combination chemotherapy abl class fusion genetic polymorphism host pharmacogenomics particular receptor enzyme regulating metabolism mercapto purine methotrexate glucocorticoid could enrolled obtain standard medium standard evaluable high high evaluable duration duration duration performed based randomized january requested data safety monitoring board november",
  "KAPKEY": "ii multicentric pembrolizumab classic endemic kaposis sarcoma classic endemic kaposis sarcoma lymphangioproliferations associated human herpes virus hhv poorly codified chemotherapy give best transient response interferon response frequent drug often poorly tolerated elderly therefore new therapy needed classic represents ideal model evaluating new drug since receive concomitant immunosuppressive regimen antiviral therapy pembrolizumab anti pharmacodynamic monoclonal antibody recently shown improve survival several solid tumor data available role pharmacodynamic pharmacodynamic axis significant pharmacodynamic expression hhv associated pleural effusion lymphoma sample recently reported experience classical endemic support role pathway expression pharmacodynamic subpopulation cell also nk cell peripheral blood cell expression pharmacodynamic tumor cell lesion evaluate benefit safety profile pembrolizumab classic endemic simon stage optimal design main objective assess whether pembrolizumab clinically inactive partial complete response probability truly active partial complete response probability classic endemic kaposis sarcoma using simon stage optimal design endpoint best overall response rate borr defined occurrence complete response partial response following actg criterion recorded start beginning specific systemic therapy occurs extension stage case truly active conclusion simon stage optimal design extension stage would performed assess precisely efficacy pembrolizumab setting included obtain precise estimation effect endpoint extension stage best overall response rate according actg criterion recorded start beginning specific systemic therapy occurs included simon stage optimal design followed objective simon stage optimal design extension stage assess safety profile pembrolizumab classic endemic kaposis sarcoma characterize efficacy pembrolizumab related pharmacodynamics assessment endpoint efficacy endpoint different aspect response evaluated best overall response rate according physical global assessment pga score beginning specific systemic therapy occurs response rate according actg pga criterion response rate number lesion best response defined following endpoint response rate size target lesion best response defined following endpoint response rate tumor infiltration target lesion best response defined following endpoint response rate lymphedema circumference scale absence painful oozing best response defined following endpoint time response defined time first response recorded start time progression response rate according actg pga criterion extension stage duration response defined time starting progression achieving partial complete response quality life following qlc dlqi_kaposi baseline cycle cycle cycle every eot early termination safety endpoint safety assessed term drug toxicity evaluated clinic laboratory parameter scored according common terminology criterion adverse event common terminology criteria for adverse events version uncontrolled open label multicentric ii adult classic endemic kaposis sarcoma meeting following criterion may included simon stage optimal design extension stage classic endemic histologically confirmed progressive disease lesion involving one limb segment involvement body surface least cutaneous lesion millimeter least cutaneous tumor available repeated pharmacodynamics evaluation willing provide tissue cutaneous biopsy tumor lesion least week washout specific therapy including chemotherapy immunotherapy provide written prior performance specific procedure age day signing performance status eastern cooperative oncology group (= performans status (= ecog)) performance scale demonstrate adequate organ function hematological absolute neutrophil count absolute neutrophil count millimeter platelet millimeter hemoglobin deciliter renal calculated creatinine clearance ml min using mdrd formula hepatic aspartate amino transferase serum glutamic oxaloacetictransferase alanine amino transferase serum glutamopyruvatetransferase xuln serum bilirubin xuln direct bilirubin upper limit of normal subject bilirubin level xuln female subject childbearing potential negative serum pregnancy within hour prior receiving first dose medication health insurance meeting following criterion must included simon stage optimal design extension stage known history organ transplantation human immunodeficiency virus human immunodeficiency virus antibody detected selection receiving systemic steroid therapy form immunosuppressive therapy within day prior first dose symptomatic visceral involvement unless therapeutic option available previously received treatment anti pharmacodynamic anti pharmacodynamic anti pharmacodynamic anti ctla antibody antibody drug specifically targeting cell costimulation immune checkpoint pathway active infectious hepatitis type hbsag detected hcv rna detected active tuberculosis bacillus tuberculosis active infection requiring systemic therapy hypersensitivity pembrolizumab excipients prior anti cancer monoclonal antibody monoclonal antibody within last week recovered grade selection adverse event due agent administered week earlier prior chemotherapy targeted small molecule therapy radiation therapy within week half life prior day recovered grade selection adverse event due previously administered agent note subject grade neuropathy exception criterion may qualify note subject received major surgery must recovered adequately toxicity complication intervention prior starting therapy known additional malignancy progressing requires active exception include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer active autoimmune disease required systemic past use disease modifying agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc considered form systemic vitiligo type diabetes mellitus hypothyroidism psoriasis non requiring systemic permitted enroll active non infectious pneumonitis known history non infectious pneumonitis required steroid severe pulmonary disease hypoxia known psychiatric substance abuse disorder would interfere cooperation requirement pregnant breastfeeding expecting conceive father child within projected duration willing use adequate contraceptive method visit throughout day last dose therapy received live vaccine within day prior first dose participating currently participating participated investigational agent within week first dose history current evidence condition therapy laboratory abnormality might confound result interfere subject full duration best interest subject participate opinion treating investigator guardianship curatorship simon stage optimal design development ii pembrolizumab route intraveinous infusion dose regimen milligrams per infusion every week duration cycle extension stage development ii pembrolizumab route intraveinous infusion dose regimen milligrams per infusion every week duration cycle confirmed complete response defined simon stage optimaldesign occurs pembrolizumab cycle complete response observed confirmed least pembrolizumab stopped uncontrolled pharmacodynamic evaluation based tumor tissue collection cutaneous biopsy correlative blood sampling simon stage optimal design receive pembrolizumab milligrams intraveinously every week assessed drug safety efficacy continue unless experience disease progression unacceptable adverse event extended case delay due adverse event resolved extension stage included extension stage receive pembrolizumab milligrams intraveinously every week assessed drug safety efficacy continue unless experience disease progression unacceptable adverse event confirmed complete response occurring lasting least simon stage optimal design enrolled first part another second part implies screen maximum extension stage additional enrolled multicenter french simon stage optimal design participating center french national group groupe de cancerologie cutanee extension stage participating center french national group groupe de cancerologie cutanee simon stage optimal design duration duration follow maximum selection cycle extended case delay due adverse event resolved follow extension stage duration duration follow maximum screening cycle extended case delay due adverse event resolved follow otal duration including extension stage simon stage optimal design ap hp saint louis ap hp avicenne ap hp cochin ap hp bichat chru de lille centre hospitalier lyon sud chru montpellier hopital saint eloi chu grenoble extension stage ap hp saint louis ap hp avicenne ap hp cochin ap hp bichat chru de lille centre hospitalier lyon sud chru montpellier hopital saint eloi chu grenoble chu marseille chu toulouse ch nice simon stage optimal design multicenter uncontrolled ii based stage ii simon optimal design sample size computation based statistical hypothesis regard effect main endpoint best overall response rate type error statistical power sample size computed assess whether drug inactive partial complete response probability truly active partial complete response probability based hypothesis computed would accrued stage necessary stopped th waiting endpoint stop conclusion inactivity response observed stage otherwise additional recruited sample size least response indicate drug effective enough case observed response end stage stage directly begin without stop extension stage included extension stage considered main analysis expected complete best overall response rate complete response partial response would obtain ci interval complete response rate equal analysis performed included extension stage plus included simon stage optimal design expected best overall response rate analysis reach ci interval complete response rate equal",
  "MSC-SLE": "severe refractory systemic lupus erythematosus injection allogeneic mesenchymal stem cell derived umbilical cord systemic lupus erythematosus sle rare prevalence person heterogeneous auto immune auto inflammatory disease autoimmune disease affecting sex race peak incidence prevalence among black people predilection woman rd th decade life sle characterized successive flare remission may vary duration quality prognosis severe form sle affect lung heart brain addition renal involvement improved still evolution remains pejorative subset whose mortality remains even tertiary referral center new prospective course sle demonstrated effectiveness new biological therapy yet made long awaited breakthrough severe sle anti blys monocolonal antibody gained indication moderately active sle addition serious adverse side effect progressive multifocal leukoencephalopathy observed several biologics autoimmune disease dampened expected benefit sle subject resistant emergency room nd line conventional need develop effective therapy fewer long term side effect based new immunomodulatory immunosuppressive strategy according vitro immunomodulatory property ability induce tissue repair mechanism mesenchymal stem cell mesenchymal stromal cells proposed new therapy several autoimmune disease including sle use allogeneic umbilical cord derived mesenchymal stromal cells based experimental human data particularly produced nanjing team professor standardization of uveitis nomenclature china also logical select sle severity criterion used worldwide validate efficacy anti blys therapy similarly analysis expected result take account criterion similar comparable used pivotal trial unique opportunity set collaboration saint louis assistance publique hôpitaux de paris expert center cell therapy autoimmune disease university college london cell manufacturing main objective assess tolerance allogeneic umbilical cord derived mesenchymal stromal cells administration severe sle refractory standard therapy cyclophosphamide mycophenolate mofetil corticosteroid without anti cd endpoint immediate tolerance assessed first injection day allogeneic mesenchymal stromal cells injection according standard common terminology criteria for adverse events side effect objective feasibility allogeneic uc mesenchymal stromal cells administration severe sle subject refractory conventional therapy tolerance three injection considering observed morbidity overall survival sle treated subject procedure analysis biological response routine biological examination criterion monitoring lupus using selena sledai bilag sf eq sri slicc sle score analysis efficacy injection allogeneic uc mesenchymal stromal cells according proportion subject major response rcm percentage subject partial response cpr follow evaluation immunomodulatory effect mesenchymal stromal cells routine laboratory criterion including immunophenotyping every follow analysis specific cytokine production analysis mesenchymal stromal cells immunogenicity endpoint safety tolerance assessed injection within first day following mesenchymal stromal cells injection according side effect defined common terminology criteria for adverse events standard miller result cancer cancer related toxicity analyzed according international world health organization maximum degree toxic attack body injection considered tolerated toxicity criterion grade proportion subject major response mcr proportion subject partial response clinic pcr follow disease activity measured bilag score selena sledai every compared end follow sri response rate measured every three follow sri response defined point reduction selena sledai score new bilag score organ one new bilag score worsening increase overall evaluation physician compared value presence comorbidities according sclicc sle index every three follow charlson comorbidity index eligibility quality life assessed short form version sf eq injection every end monitoring percentage subject average dose prednisone reduced compared milligrams day week average daily corticosteroid dose measured every end monitoring mo number failure defined one following end stage renal disease requiring dialysis transplantation sustained doubled creatinine value two lowest value observed screening baseline confirmed four week later active lupus nephritis attributed active sle defined either two criterion doubling value proteinuria proteinuria hour subject hour baseline proteinuria hour subject hour baseline ii nephropathy increase serum creatinine respect value baseline simultaneously value proteinuria doubled least hour hematuria two positive urine test strip presence cell cylinder two criterion must confirmed twice week interval need steroid therapy intravenously plasmapheresis immunoglobulin intravenous infusion immunosuppressive therapy treat aggravation sle standard immunological biological marker including lymphocyte immuno phenotyping complete blood count creatinine proteinuria autoantibody anti dna antibody native ana complement system ch immunophenotyping every three follow specific cytokine production analysis mesenchymal stromal cells immunogenicity according anti human leukocyte antigen antibody dosage cross match analysis single center ii open national recruitment within fai network sle active subject refractory prior standard therapy age diagnosis systemic lupus erythematosus sle according american college of rheumatology criterion positive antinuclear antibody subject sustained disease activity defined selena sledai sle activity index baseline inefficacy adverse effect necessitating discontinuation first second line therapy sle including prednisone orally milligrams day equivalent least day least one following immunosuppressive therapy cyclophosphamide intravenous infusion bolus milligrams minimum ii mycophenolate mofetil orally equivalent dose milligrams day least day iii azathioprine orally dose milligrams kilograms day least day intravenous infusion methotrexate orally parenterally dos milligrams week least day leflunomide orally dose milligrams day least day vi rituximab anti cd intravenous bolus milligrams week four week dose twice day two week vii cyclosporine orally dose milligrams kilograms day least day viii belimumab intravenously subcutaneous monthly bolus milligrams kilograms infusion least received sle stable dos minimum day prior eligibility including one following treatment prednisone equivalent alone combined antimalarial anti inflammatory steroidal immunosuppressant negative pregnancy test woman childbearing age men woman using effective contraceptive method within end men partner childbearing age signed affiliation social security subject pregnancy breastfeeding lack appropriate contraception duration presence renal failure calculated creatinine clearance ml min cardiac failure sign congestive heart failure left ventricular ejection fraction echocardiography uncontrolled ventricular arrhythmia hepatitis defined abnormal level transaminase aspartate amino transferase alanine amino transferase normal related disease activity respiratory disease mean pap mmhg echocardiography respiratory failure defined resting blood pressure oxygen pao mmhg paco mmhg without oxygen severe psychiatric disorder including severe psychosis related sle would prevent give undergo procedure active neoplasia concomitant myelodysplasia except basal cell carcinoma squamous cell carcinoma situ cervix carcinoma bone marrow failure defined neutropenia thrombocytopenia anemia deciliter lymphopenia cd caused another disease sle acute chronic uncontrolled infection human immunodeficiency virus htlv hepatitis hb ag surface antigen hepatitis positive pcr optional pcr received belimumab intravenously subcutaneous within baseline received rituximab cell depleting biologic therapy within baseline current substance abuse recent within day history substance abuse exclusion national roster researcher linguistic psychological incapacity sign already included another time poor compliance legal protection ii allogeneic umbilical cord derived mesenchymal stromal cells injected slow intravenous infusion according weight recipient group dos csm kilograms csm kilograms csm kilograms injection min intravenous infusion na na level immunosuppressive immunomodulatory action allogeneic mesenchymal stromal cells umbilical cord healthy donor allow beneficial action severe sle resistant conventional treatment monocentric st louis hospital follow duration per per site initially subject initial dose csm kilograms recipient weight included following subject enrolled dose kilograms high probability excessive toxicity mesenchymal stromal cells kilograms csm kilograms low probability excessive toxicity csm kilograms toxicity criterion described common terminology criteria for adverse events classification cohort scanned sequential bayesian approach estimate probability toxicity administered dose allowing adaptation function toxicity observed dose previous subject",
  "ERYTHROSIM": "randomized prospective evaluating efficacy anticd monoclonal antibody isatuximab pcra major abo mismatch allogeneic hematopoietic stem cell transplantation quarter allogeneic hematopoietic stem cell transplantation performed situation major abo mismatch exposing immunological pure red cell aplasia prca transplant pcra transplant defined anemia low reticulocyte count day despite good leucocyte platelet engraftment full donor chimerism associated persistence recipient hemagglutinins anti anti antibody bone marrow evaluation performed show erythroid hypoplasia red blood cell transfusion necessary every two week remission leading impaired quality life anemia repeated hospitalization iron overload need iron chelation therapy treatment currently used inefficient anti cd monoclonal antibody epo steroid plasma exchange proteasome inhibitor severe acute graft versus host disease donor lymphocyte infusion prca demonstrated associated persistence recipient plasma cell anti cd monoclonal antibody target plasma cell secreting hemagglutinins responsible pcra promising case reported literature support rapid sustain efficacy chapuy nejm bathini amjhematol rautenberg bmt salas others eur haematol preethi others blood cell mol dis yates others transfusion prospective randomized evaluation efficacy safety context necessary main objective efficacy prca isatuximab allogeneic hematopoietic stem cell transplant compared supportive care control group reduction prca resolution time day endpoint time obtention transfusion independence prca time interval randomization corresponding post transplant resolution prca date resolution reticulocytopenia treated anti cd monoclonal antibody isatuximab objective evaluate two arm term biological outcome reduction red blood cell transfusion need isatuximab evolution iron overload adverse event related isatuximab context allogeneic sct ctc adverse event grade group post transplant quality life functional repercussion chronic anemia iterative transfusion iron overload randomization overall survival without relapse post transplant identify prognostic factor spontaneous resolution prca major abo mismatch type donor cell stem cell conditioning regimen occurrence acute chronic graft versus host disease discontinuation immunosuppression evaluate interest follow group hemagglutinins compare arm term cost effectiveness cost isatuximab hospitalization transfusion support chelation treatment endpoint number red blood cell transfusion randomization ferritin level post transplant adverse event ctc adverse event grade randomization quality life questionnaire eortc qlq post transplant factor associated spontaneous resolution prca post transplant antibody level anti anti titer post transplant visit post randomization number day hospitalization transfusion support chelation treatment randomized prospective ii assessing efficacy safety anticd antibody isatuximab persistent prca allogeneic hematopoietic stem cell transplantation including day transplant help define factor associated unresolved prca thus identify could benefit isatuximab earlier future interim analysis performed observation event endpoint allogeneic stem cell transplant recipient age older prca aged older receiving allogeneic hematopoietic stem cell transplantation condition major abo mismatch pcra defined persistent red blood cell transfusion dependence day post transplant reticulocyte count despite full donor chimerism good leucocyte platelet recovery relapse progression underlying disease contraception method must prescribed duration using effective contraceptive method woman childbearing age continue abstinence heterosexual intercourse accepted man least last dose refrain donating sperm health insurance coverage signed written parent aged less aged relapse underlying disease leucocyte chimerism prca related parvovirus infection positive blood pcr known human immunodeficiency virus hepatitis active infection active tuberculosis pregnancy hcg positive breast feeding receiving recombinant human erythropoietin receiving proteasome inhibitor bortezomib example receiving thrombopoietin receptor agonist artpo receiving plasma plasmapheresis exchange transplant planned receive investigational drug within day half life investigational drug whichever longer clinically significant uncontrolled medical condition investigator opinion would expose excessive may interfere compliance interpretation result hypersensitivity active substance history intolerance steroid mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer sucrose component therapy amenable premedication steroid blocker would prohibit agent debilitating medical psychiatric illness tutorship curatorship understand optimal follow isatuximab dose milligrams kilograms intravenous route first injection isatuximab performed randomization day second injection may performed reticulocyte third reticulocyte assessed day day day day randomization supportive care allowed pre medication infusion isatuximab follow hemagglutinin antibody titer anti anti titer kinetic immunologic reconstitution pcr hbv donor recipient history hbv infection early prca remission first injection isatuximab improvement quality life group global cost reduction isatuximab arm major added experimental adverse event expected occurrence reaction infusion fever chill asthenia nausea desaturation bronchospasm grade diarrhea grade occurrence pneumonia hypogammaglobulinemia randomized increased include even expected randomize needed notably less enrolled still prca center pediatrics adult france post transplant post randomization duration center center bilateral logrank test considering sample size randomized experimental group median transfusion independence control group median transfusion independence achieves power alpha considering included randomized included interim analysis performed observation event endpoint",
  "EQUAALL01": "evaluation long term health status quality life adult survivor philadelphia negative acute lymphoblastic leukemia lymphoma treated intensive pediatric pediatric inspired inspired protocol overall survival adult philadelphia negative acute lymphoblastic leukemia lymphoma dramatically improved use full pediatric pediatric inspired protocol graall fralle aimed reduce relapse adopting intensive chemotherapeutical schedule approach led global improvement overall survival whatever age responsible excess related mortality older trm pediatric longitudinal pointed long term leukemia survivor increased developing specific adverse event like dysmetabolic syndrome obesity decreased fertility organ dysfunction osseous event impaired cognitive function aim evaluate impact term long term event quality of life adult received intensified therapeutic approach recently implemented adult cooperative group evaluate prevalence late effect adult treated ago intensified pediatric inspired protocol graall fralle exposed increased cumulative dos chemotherapy central nervous system irradiation allogeneic transplant body irradiation based regimen boost irradiation central nevous system endpoint thus defined prevalence adverse event including metabolic trouble dysmetabolic syndrome dyslipidemia diabetes osseous event osteoporosis cardiac vascular trouble neurologic trouble lung dysfunction endocrinal trouble ophthalmological trouble fertility disorder neoplasia evaluate quality life correlate prevalence late effect quality of life status previous social situation previous medical condition scheme including administration protocol delayed intensification maintenance central nervous system irradiation allogeneic sct graft versus host disease occurrence elaborate adapted recommendation long term follow adult treated reinforced therapeutic strategy endpoint thus prevalence metabolic trouble dysmetabolic syndrome dyslipidemia diabetes prevalence osseous event osteoporosis prevalence cardiac vascular trouble prevalence neurologic trouble prevalence lung dysfunction prevalence endocrinal trouble quality life sf prevalence ophthalmological trouble prevalence fertility disorder prevalence neoplasia multicenter cross sectional interventional minimal constraint human research adult aged diagnosis treated ten ago hydrogen ion concentration negative acute lymphoblastic leukemia lymphoma philadelphia negative treated according pediatric like pediatric inspired protocol graall fralle without allogeneic transplant older old less old diagnosis follow first complete remission gave signed baseline examination experienced relapse within past philadelphia positive none hormons test antral follicle count questionnaire expected individual benefit since systematic review used detect take early care late complication related none minimal approximatively center graall network state duration site site analysis handle left data truncation given survive able included approximately included graall among august considering alive last follow opportunity include treated according protocol success approximately recruited allows assessing prevalence trouble ci width assuming prevalence assuming prevalence detection respectively also allows reaching statistical power least detecting",
  "MSC-AT-SSc": "ii randomized allogeneic adipose tissue derived mesenchymal stromal cell systemic infusion severe systemic sclerosis systemic sclerosis systemic sclerosis rare severe chronic systemic autoimmune disease autoimmune disease characterized vasculopathy immune dysregulation fibrosis leading multi organ dysfunction primarily skin lung heart gastrointestinal tract kidney high morbidity mortality altered health related quality life high cost society mostly symptomatic autologous hematopoietic stem cell transplantation autologous hematopoietic stem cell transplantation shown long term improvement overall event free survival disease modifying property however autologous hematopoietic stem cell transplantation contra indicated case advanced visceral involvement eligible still associated toxicity urgent need identify safe effective treatment severe systemic sclerosis mesenchymal stromal cell mesenchymal stromal cells multipotent cell carry immunomodulatory pro angiogenic anti fibrotic property target systemic sclerosis pathogenesis manifestation increasing use mesenchymal stromal cells harvested bone marrow mesenchymal stromal cells adipose tissue mesenchymal stromal cells umbilical cord mesenchymal stromal cells uc variety indication provides consistent evidence supporting safety human efficacy mesenchymal stromal cells intravenous intravenous infusion injection treating acute graft versus host disease led marketing approval mesenchymal stromal cells alofisel approved severe crohn fistula mesenchymal stromal cells represent promising therapeutic approach systemic sclerosis previously shown disease specific abnormality mesenchymal stromal cells systemic sclerosis providing strong rationale use allogeneic mesenchymal stromal cells treat systemic sclerosis published first ii dose escalation using allogenic mesenchymal stromal cells infusion severe systemic sclerosis clinicaltrials gov nct programme hospitalier de recherche clinique aom safety issue significant improvement skin fibrosis infusion appeared lower thereafter thereby supporting need repeated infusion vitro experimental suggest mesenchymal stromal cells property vary according tissue origin source demonstrated compared mesenchymal stromal cells mesenchymal stromal cells easier harvest display higher proliferative capability entering senescence higher genetic stability superior immunosuppressive property considering rationale hypothesize use healthy donor allogeneic mesenchymal stromal cells produced etablissement francais du sang event-free survival demonstrate safety issue efficacy profile increase repeated infusion allogeneic mesenchymal stromal cells treat systemic sclerosis main objective evaluate safety one allogeneic mesenchymal stromal cells kilograms intravenous administration twice interval severe systemic sclerosis endpoint rate related severe adverse event severe adverse event defined adverse event adverse event grade equal using national cancer institute common terminology criterion adverse event common terminology criteria for adverse events classification one infusion adverse event adjudicated data safety monitoring committee objective safety infusion within first hour infusion follow efficacy signal inform future using outcome measure skin sclerosis lung function quality life previously validated systemic sclerosis used cell therapy trial analysis response progression free survival progression-free survival global rank composite score global rank composite score american college of rheumatology provisional composite response index trial early diffuse cutaneous systemic sclerosis acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis early systemic sclerosis analysis overall survival assess cause death impact allogeneic mesenchymal stromal cells intravenous infusion twice interval immune response including immunophenotyping alloimmunization starting therapy cost effectiveness allogeneic mesenchymal stromal cells infusion twice versus severe systemic sclerosis endpoint rate related severe adverse event defined adverse event grade equal common terminology criteria for adverse events time within first hour infusion follow main efficacy endpoint modified rodnan skin score mrs difference efficacy disease related endpoint mrs performance status health related quality life health-related quality of life questionnaire scleroderma health assessment questionnaire scleroderma-health assessment questionnaire short form health survey sf eq forced vital capacity forced vital capacity diffusing capacity lung carbon monoxide diffusing capacity of lung for carbon monoxide response defined following decreased mrs increased forced vital capacity increased diffusing capacity of lung for carbon monoxide without need immunosuppression except low dose steroid milligrams daily progression-free survival progression defined following decreased forced vital capacity diffusing capacity of lung for carbon monoxide decrease lvef decrease weight decrease creatinine clearance increased mrs increase scleroderma-health assessment questionnaire global rank composite score value acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis value early systemic sclerosis overall survival myeloid lymphocyte sub population included alloimmunization included detection identification donor specific anti human leukocyte antigen antibody extra cost per quality-adjusted life quality adjusted life gained unique repeated intravenous infusion infusion allogeneic mesenchymal stromal cells severe systemic sclerosis extra cost per severe adverse event grade equal common terminology criteria for adverse events avoided unique repeated intravenous infusion infusion allogeneic mesenchymal stromal cells severe systemic sclerosis multi centre three arm randomized placebo controlled double blind ii adult refractory severe systemic scleroderma provide signed dated willing comply procedure available duration male female aged age systemic sclerosis according american college rheumatology european league rheumatism american college of rheumatology european league against rheumatism classification criterion systemic sclerosis severe disease either disease duration less modified rodnan skin score mrs abnormal c reactive protein milligrams hemoglobin deciliter mrs without restriction disease duration plus least one major organ involvement defined respiratory involvement consisting lung diffusion capacity carbon monoxide diffusing capacity of lung for carbon monoxide forced vital capacity forced vital capacity predicted evidence interstitial lung disease chest ray high resolution computed tomography hrct scan moderate pulmonary hypertension baseline resting systolic pulmonary arterial pressure mmhg mmhg cardiac echocardiography mean pulmonary artery pressure mmhg millimeter hg right heart catheterization renal involvement consisting past renal crisis microangiopathic hemolytic anemia renal insufficiency explained cause systemic sclerosis cardiac involvement consisting reversible congestive heart failure atrial ventricular rhythm disturbance recurrent episode atrial fibrillation flutter recurrent atrial paroxysmal tachycardia nd rd degree av block mild moderate pericardial effusion presence magnetic resonance imaging involvement increased mapping late gadolinium enhancement septal sign cause organ involvement attributed systemic sclerosis contraindication inadequate response unwillingness undergo autologous hematopoietic stem cell transplantation determined physician judgement contraindication inadequate response unwillingness adverse event necessitating discontinuation conventional immunosuppressive therapy mycophenolate mofetil methotrexate woman reproductive potential must use highly effective contraception men reproductive potential must use condom health insurance nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable implantable progestogen hormonal contraception intrauterine device intrauterine device intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom age pregnancy unwillingness use adequate contraception life threatening end organ damage defined diffusing capacity of lung for carbon monoxide corrected hemoglobin predicted left ventricular ejection fraction cardiac echocardiography pulmonary hypertension baseline resting systolic pulmonary arterial pressure mmhg cardiac echocardiography mean pulmonary artery pressure mmhg right heart catheterization glomerular filtration rate ml min active chronic hepatitis aspartate amino transferase alanine-aminotransferase upper limit normal neoplasm less except basal cell situ cervix carcinoma concurrent myelodysplasia uncontrolled hypertension uncontrolled acute chronic infection human immunodeficiency virus human immunodeficiency virus infection body mass index kilograms severe psychiatric disorder bone marrow insufficiency defined neutropenia thrombopenia anemia deciliter lymphopenia inability provide included another interventional tutelle allogeneic adipose tissue derived mesenchymal stromal cells mesenchymal stromal cells placebo injected slow intravenous infusion according recipient body weight experimental arm arm placebo arm mesenchymal stromal cells cell kilograms injection placebo injection arm mesenchymal stromal cells cell kilograms injection mesenchymal stromal cells cell kilograms injection allogeneic mesenchymal stromal cells administered intravenously min infusion second infusion drug product mesenchymal stromal cells placebo performed absence related severe adverse event trsae included arm arm opportunity according willingness receive either arm arm mesenchymal stromal cells cell kilograms injection end unblinding evidence mesenchymal stromal cells injection safety provided placebo administration allogeneic adipose tissue derived mesenchymal stromal cells mesenchymal stromal cells two injection placebo two injection supplementary visit injection basic blood urine evaluation supplementary blood sampling eligibility evaluation infectious serology hcg woman advanced immunophenotyping alloimmunisation investigation baseline follow evaluation constitution biological sample collection skin biopsy optional notebook cost effectiveness analysis based strong experimental data copi tarte published result team severe systemic sclerosis previously treated single intravenous infusion allogeneic mesenchymal stromal cells infusion nct strong rationale systemic sclerosis symptom improved mesenchymal stromal cells least fibrosis skin score regression lung function stabilization result proposed used inform larger ii iii multi center mesenchymal stromal cells systemic sclerosis trial auto immune disease potential accelerate systemic sclerosis allow france playing leadership role regenerative medicine autoimmune disease fibrotic disease increasing use mesenchymal stromal cells wide variety therapeutic indication currently provides wealth data favour safety human foreseeable serious adverse effect associated injection mesenchymal stromal cells transient benign adverse reaction linked procedure injecting cell placebo may occur centre unite de medecine interne uf mathec centre de reference de malady auto immune systemiques rares dile de france filiere fai irsl urp universite de paris hopital st louis ap hp avenue claude vellefaux paris france dominique farge md phd centre recruitment follow unite de medecine interne uf mathec centre de reference de malady auto immune systemiques rares dile de france filiere fai irsl urp universite de paris hopital st louis ap hp avenue claude vellefaux paris france dominique farge md phd service de medecine interne et immunologie clinique pole hospitalo universitaire de malady digestive chu rangueil bat eme etage avenue du professor jean poulhes tsa toulouse cedex gregory pugnet md phd follow plus possibly additional follow placebo arm arm arm chosen opportunity receive one two mesenchymal stromal cells injection end unblinding evidence mesenchymal stromal cells injection safety provided unblinding mesenchymal stromal cells injection duration per site per propose conduct multi center three arm randomized double blind placebo controlled enroll systemic sclerosis randomized one two arm infusion mesenchymal stromal cells infusion mesenchymal stromal cells placebo arm per arm using randomization block size staggered allow detection severe adverse event prior subsequent according following waiting rule least one week two consecutive randomization interval least one every three randomization continuous monitoring endpoint sponsor implemented allow continuous bayesian toxicity monitoring stopping rule implemented endpoint cell infusion see section detail first analysis first completed visit analysis trsae visit final analysis stopping rule defined based estimated probability related severe adverse event trsae criterion probability posteriori probability severe adverse event posterior probability trsae trsae estimated using bayesian approach beta density stopping rule fulfilled criterion meaning high probability greater trsae interim analysis result presented data safety monitoring board recommendation case early stopping subsequent randomized treated thus far followed result analyzed described formal statistical test sample size bayesian framework nevertheless one invoke frequentist framework anticipate expected precision term safety indeed infusion infusion infusion able estimate severe adverse event severe adverse event width exact confidence interval equal considering independence infusion",
  "DREPA-RIC": "prospective multicenter comparing allogeneic matched related haematopoietic stem cell transplantation reduced intensity conditioning regimen standard care adolescent adult severe sickle cell disease although survival child sickle cell disease scd dramatically improved last decade europe mortality remains high adult moreover many child adult develop chronic debilitating condition due organ damage allogeneic hematopoietic stem cell transplantation hematopoietic stem cell transplantation currently unique curative approach allows cure child transplanted matched related donor minimal residual disease myeloablative conditioning regimen date addressed role hematopoietic stem cell transplantation scd adult due graft versus host disease graft versus host disease toxicity expected older higher organ damage development safe non myeloablative conditioning regimen allow stable mixed chimerism avoid graft versus host disease appears attractive option hematopoietic stem cell transplantation cure adult severe scd four group previously reported encouraging result transplanted matched related mobilized peripheral blood cell non myeloablative conditioning regimen alemtuzumab low dose body irradiation body irradiation followed post transplant sirolimus demonstrate high scd free survival rate death related transplant graft failure graft versus host disease ninety two percent cured normalized hemoglobin level resolution hemolysis stable hemoglobin level identical proportion observed donor however outcome comparison transplanted transplanted lacking design prospective multicenter targeting severe scd compare non myeloablative transplant matched related donor minimal residual disease identified versus hematopoietic stem cell transplantation lacking minimal residual disease main objective assess benefit hematopoietic stem cell transplantation event free survival calculated compared standard care endpoint event free survival event defined death cause acute grade ii intravenous infusion graft versus host disease according magic consortium appendix moderate severe chronic graft versus host disease according nih classification hospitalization voc defined according usual criterion one ac defined usual criterion pulmonary infiltrate chest film thoracic computed tomography ct scan stroke defined event confirmed magnetic resonance imaging cerebral cervical stenosis new territory evaluated magnetic resonance imaging mra increased least tricuspid regurgitation velocity confirmed echocardiography performed delay least compared pre value trv apparition silent infarct cerebral cervical stenosis new territory increase previous stenosis evaluated magnetic resonance imaging mra hypothesize event free survival hematopoietic stem cell transplantation versus transplant group objective compare group overall survival day requiring hospitalization first post acute complication scd voc ac priapism stroke silent infarct cerebral cervical stenosis mra magnetic resonance imaging hemolytic index hematologic biochemical parameter organ function kidney eye heart lung liver bone grade iii intravenous infusion infectious complication need transfusion post alloimmunization rate iron overload chronic used oral opioids nutritional involvement gonadic function fertility quality life anxiety depression cost red blood cells white blood cell count adherence evaluate transplant group chimerism engraftment graft versus host disease free sirolimus post transplant end point death number day requiring hospitalization exclusion first post adverse event number voc ac requiring hospitalization number hospitalization intensive care unit number priapism number stroke change biological parameter ldh aminotransferase gamma gt alkaline phosphatase bilirubin professor aptt hemoglobin level hematocrit mean corpuscular volume percentage hemoglobin variant reticulocyte white blood cell platelet count estimated glomerular function rate microalbuminuria creatininuria ratio ferritin transferrin saturation level gonadic function spermogram men lh fsh oestrogen woman testosterone men number amenorrhea woman number parity eye function heart pulmonary hypertension auricular ventricular dilatation left ventricular mass function transthoracic echocardiography lung function pulmonary function test min walk test bone function new episode avascular osteonecrosis fracture central nervous system function mra magnetic resonance imaging liver heart magnetic resonance imaging iron overload evaluation ferritin microg number red blood cell packed transfused post number delayed hemolytic transfusion reaction dhtr oral opioid consumption quality life questionnaire mo sf hospital anxiety depression scale hads questionnaire change weight severe infection ctae score grade graft versus host disease incidence grading hematopoietic stem cell transplantation chimerism hematopoietic stem cell transplantation assessed blood population lymphocyte subset cost evaluated day hospitalization red blood cells white blood cell count adherence expression red blood cells white blood cell count surface marker lymphocyte subpopulation quasi experimental design prospective controlled multicenter cohort group defined genetic randomization eligibility criterion obtained human leukocyte antigen typing performed identify potential human leukocyte antigen minimal residual disease define group group exposed human leukocyte antigen identical sibling identified receive hematopoietic stem cell transplantation group unexposed lacking human leukocyte antigen identical sibling received best standard care transplant arm red cell exchange performed reduce hemoglobin level less preparative regimen conditioning regimen consist cgy body irradiation alemtuzumab intravenous infusion dose milligrams kilograms day stem cell source cerebro spinal fluid mobilized peripheral blood stem cell cd target dose per kilograms body weight graft versus host disease prophylaxis consist sirolimus sirolimus tapered stopped post transplant transplant arm receive best standard care according situation previous initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation transfusion program time point initiation new drug proved improve scd authorization use france adolescent young adult scd aged least one non scd sibling parental couple presented least one following criterion voc requiring hospitalization last least severe ac within past defined followed ac requiring red cell transfusion hospitalization intensive care unit ac pao mmhg arterial blood hydrogen ion concentration pac mmhg need liter mn reaching sat voc requiring hospitalization last history recurrent ac three history ischemic stroke cerebral cervical arterial stenosis apparition silent infarct last pulmonary hypertension defined mean pulmonary artery pressure mmhg rest determined right heart catherization osteonecrosis least joint including one diagnosed past sickle nephropathy estimated glomerular filtration rate ckd epi formula ml min persistant microalbuminuria microalbuminuria creatininuria ratio milligrams mmol without cause nephropathy requiring hydroxyurea chronic transfusion already treated hydroxyurea transfusion program time point already receiving chronic transfusion voc ac responding hydroxyurea eligible provided least voc requiring hospitalization one within past initiation chronic transfusion least past history ac contraception sirolimus woman child bearing potential signed amenable human leukocyte antigen typing hematopoietic stem cell transplantation human leukocyte antigen identical sibling available affiliated french health care insurance age hb electrophoresis aa ac donor usual biological eligibility criterion cerebro spinal fluid mobilization peripheral blood stem cell bone collection including legal viral serology assessment authorizing transplant human leukocyte antigen identical negative covid test time hematopoietic stem cell transplantation mobilization performance status eastern cooperative oncology group (= performans status (= ecog)) scale pulmonary function fev et forced vital capacity theorical value post capillary severe pre capillary pulmonary hypertension measured mean pulmonary artery pressure rest mmhg cardiac ejection fraction estimated glomerular fraction rate gfr ml mn conjugate bilirubin mole cirrhosis alanine-aminotransferase uncontrolled infection known hypersensitivity alemtuzumab known hypersensitivity murin protein following excipients disodium edetate polysorbate potassium chloride potassium phosphate monobasic sodium chloride dibasic sodium phosphate water injection positivity human immunodeficiency virus pregnancy breast feeding woman alloimmunization delayed hemolytic transfusion reaction precluding red cell transfusion previous solid organ transplant hematopoietic stem cell transplant transplanted within human leukocyte antigen matched related hematopoietic stem cell transplantation red cell exchange performed reduce hemoglobin level less preparative regimen consider fertility preservation technique according age pregnancy wish evaluation ovarian function conditioning regimen consist cgy body irradiation alemtuzumab intravenous infusion dose milligrams kilograms day stem cell source cerebro spinal fluid mobilized peripheral blood stem cell cd target dose per kilograms body weight number cd cell obtained one leukapheresis second planned next day reach goal graft versus host disease prophylaxis consisted sirolimus sirolimus tapered stopped post transplant receive best standard care according situation previous initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation time point initiation new drug proved improve scd authorization use france hematopoietic stem cell transplantation transplant arm benefit expected cure disease absence post transplant new complication related scd transplant arm complication disease despite supportive care including hydroxyurea transfusion program chronic transfusion lead iron overload alloimmunization hydroxyurea lead hypofertility arm consultation every transplant arm hospitalization week followed weekly consultation first post transplant monthly consultation consultation every common toxicity associated transplantation including reduced conditioning regimen graft versus host disease prophylaxis graft versus host disease according magic consortium appendix criterion chronic graft versus host disease according nih classification infection fever aplasia pancytopenia neutropenia thrombopenia anemia gastrointestinal nausea vomiting cardiovascular arterial hypertension neurological disorder visual disorder miscellaneous serum sickness skin rash pain swelling joint anaphylaxis hypotension difficulty breathing severe hive mucositis transplant may potentially lead transplant related mortality graft versus host disease case observed first case reported literature long term complication infertility remains evaluated setting ric transplant hematology haemovigilance therapeutic transfusion centre recruiting centre transplant centre recruiting site also transplant state follow duration expected per recruiting site per single efficacy analysis planned event-free survival compared two group using log rank test effect hematopoietic stem cell transplantation assessed hazard ratio using cox model endpoint event free survival calculated event defined followed death cause acute grade ii intravenous infusion graft versus host disease according magic consortium appendix moderate severe chronic graft versus host disease according nih classification hospitalization voc defined according usual criterion one ac defined usual criterion pulmonary infiltrate chest film thoracic computed tomography ct scan stroke defined event confirmed magnetic resonance imaging cerebral cervical stenosis new territory evaluated magnetic resonance imaging mra increased least tricuspid regurgitation velocity confirmed echocardiography performed delay least compared pre value trv apparition silent infarct cerebral cervical stenosis new territory increase previous stenosis evaluated magnetic resonance imaging mra event free survival calculated also described hematopoietic stem cell transplantation group overall survival defined time date death due cause date last follow propensity score matching analysis also performed sensitivity analysis handle potential residual imbalance arm confounders sequential analysis tolerance data performed using bayesian method hypothesize event free survival hematopoietic stem cell transplantation versus transplant group",
  "TRIBECA:": "multicenter randomized double blind comparing efficacy safety belimumab non infectious active cryoglobulinemia vasculitis compared placebo cryoglobulinemia vasculitis associated significant morbidity mortality requires therapeutic intervention management noninfectious mixed cryoglobulinemia vasculitis currently based corticosteroid rituximab last decade several group reported efficacy anti cd monoclonal antibody rituximab cryoglobulinemia vasculitis rituximab infusion proved effective main vasculitis sign complete response however cryoglobulinemic vasculitis relapse noted within day nineteen last rituximab infusion previously shown serum blys concentration correlated serum cryoglobulin level cryoglobulinemia vasculitis cryoglobulinemia associated non hodgkin lymphoma agreement data systemic lupus erythematosus sjogrens syndrome also observed decrease blys binding br staining correlated disease severity following rituximab serum blys concentration significantly increased may favour survival autoreactive cell clone relapse cryoglobulinemia vasculitis recent shown rituximab reset defective early cell tolerance checkpoint obvious solution prevent rise baff level precipitating flare disease following rituximab therapy thus achieve sustained remission disease would combine rituximab baff blockade mouse combination cell depletion baff inhibition remove cell marginal zone follicular compartment effectively either alone combination cell depletion baff blockade superior cell depletion alone respect reducing number plasmablast plasma cell well reducing disease severity three different mouse model lupus addition promising result observed cryoglobulinemia vasculitis treated rituximab plus belimumab good safety profile evaluate efficacy belimumab compared placebo non infectious active cryoglobulinemia vasculitis complete response rate vasculitis symptom week corticosteroid withdrawal prednisone milligrams day week objective safety tolerability treatment assessed frequency severity adverse event complete partial improvement organ involved baseline non improvement response rate rate complete renal response rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization complement level early failure rate non response relapse rate time relapse two treatment group cumulative dose corticosteroid received two treatment group evolution gammaglobulin cd cell level quality life score sf appendix two group rate infection severe complication lymphoma bvas activity score appendix endpoint safety tolerability treatment assessed frequency severity adverse event complete partial non response rate complete renal response rate rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization complement level rate early failure non response relapse rate defined de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis week follow rate time relapse baseline cumulative dose prednisone quality life score sf baseline rate infection severe complication week follow evolution gammaglobulin cd level baseline bvas activity score baseline bayesian ii randomized aim evaluating best strategy cryoglobulinemia vasculitis based difference response rate measured week randomization adult non infectious active cryoglobulinemia vasculitis age written inform active cryoglobulinemia vasculitis initiation rituximab define clinically active vasculitis skin joint renal peripheral nerve central neurological digestive pulmonary cardiac involvement history positive cryoglobulinemia affiliated national french social security system received rituximab induction therapy within week infusion dose discretion investigator female subject childbearing potential must negative serum urinary pregnancy test visit confirmed monthly least day half life post last dose subject reproductive potential male female willingness use contraceptive measure adequate prevent subject subject partner becoming pregnant week prior administration st dose agent day last dose agent therefore subject agree following complete abstinence intercourse week prior administration st dose agent day last dose agent sexual inactivity abstinence must consistent preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal post ovulation method withdrawal acceptable method contraception consistent correct use following acceptable method birth control prior start agent day last dose agent oral contraceptive either combined progestogen alone injectable progestogen implant levonorgestrel etonogestrel estrogenic vaginal ring percutaneous contraceptive patch intrauterine device intrauterine device intrauterine system ius failure rate stated product label male partner sterilization vasectomy documentation azoospermia prior female subject entry male sole partner subject definition documented refers outcome investigator designees medical examination subject review subject medical history eligibility obtained via verbal interview subject subject medical record double barrier method condom occlusive cap diaphragm cervical vault cap plus spermicidal agent foam gel film cream suppository allowed method contraception effective used consistently correctly accordance product label investigator responsible ensuring subject understand properly use method contraception human immunodeficiency virus negative serology negative hb ag test hbc ab test hcv negative serology negative hcv rna positive hcv serology within neutrophil absolute neutrophil count vasculitis unrelated cryoglobulinemia non active cryoglobulinemia vasculitis initiation rituximab inactive vasculitis following rituximab administration may included excluded concomitant medication day prior investigational medicinal product belimumab placebo biologic investigational agent abetimus sodium anti cd antibody bg idec investigational agent applies drug approved sale country used day prior investigational medicinal product belimumab placebo intravenous cyclophosphamide day prior investigational medicinal product belimumab placebo half life whichever greater non biologic investigational agent investigational agent applies drug approved sale country use live vaccine within day prior baseline concurrently investigational medicinal product belimumab placebo history malignant neoplasm within last carcinoma situ cervix excised basal cell squamous cell carcinoma skin low grade hemopathy indication specific progressive multifocal leukoencephalopathy evidence serious suicide including history suicidal behaviour last suicidal ideation last investigator judgment pose significant suicide history immunodeficiency significant igg deficiency igg level milligrams deciliter significant iga deficiency iga level milligrams deciliter according result obtained within prior visit history major organ transplant hematopoietic stem cell marrow transplant renal transplant infection history currently suppressive therapy chronic infection tuberculosis pneumocystis cytomegalovirus infection requiring hospitalization use parenteral intravenous infusion intramuscular antibiotic antibacterial antiviral anti fungals anti parasitic agent within day visit current drug alcohol abuse dependence history drug alcohol abuse dependence within day prior visit historically positive human immunodeficiency virus test according result obtained within prior visit hepatitis status according result obtained within prior visit serologic evidence current past hepatitis hb infection based result testing hbsag hbcab follows positive hbsag hbcab excluded positive test hepatitis rna history hypersensitivity anaphylactic reaction parenteral administration belimumab corticosteroid excipients treatment administered woman child bearing potential wcbp included please see special instruction criterion pregnant breast feeding woman intercurrent significant medical psychiatric illness investigator considers would make candidate unsuitable legal protection unable another interventional belimumab benlysta administered subcutaneously milligrams weekly week placebo belimumab administered subcutaneously weekly week ii prospective randomized multicentre double blind group belimumab administered subcutaneously milligrams weekly week group ii placebo belimumab administered subcutaneously weekly week randomization centralized stratified previous history naive versus relapsing severity vasculitis extensive skin necrosis glomerulonephritis multiple mononeuropathy myocarditis digestive central nervous system specific involvement ratio group group corticosteroid tapering scheme initial dose milligrams day following schedule reduction prednisone apply group long disease inactive milligrams day week milligrams day milligrams day milligrams day milligrams day strategy stopping glucocorticoid left investigator discretion stopping glucocorticoid therapy step prednisone dose reduced absence sign vasculitis activity arm multicentre national including centre duration duration duration week duration centre bayesian ii randomized aim evaluating strategy cryoglobulinemia vasculitis based difference response rate measured week randomization randomized ii trial still poorly used still large use single arm ii result interpreted relative historical control subject introducing selection bias confounding may limit validity conclusion thus planning ii randomized appears worthy investment considering finite financial resource design adapted binary outcome observed end fixed follow analyzed using absolute difference proportion shown greatly reduce sample size requirement thus used approach ii randomized trial proposed simon wittes ellenberg aim controlling probability detecting given difference response rate hypothesize receiving placebo belimumab treated belimumab achieve complete remission cryoglobulinemia vasculitis week steroid therapy stopped milligrams day",
  "KAPVEC": "ii multicenter talimogene laherparepvec classic endemic kaposi sarcoma kaposi sarcoma lymphangioproliferation associated human herpes virus hhv promoted immunosuppression human immunodeficiency virus related iatrogenic posttransplantation treated immune restoration association local systemic therapy chemotherapy required conversely classic endemic underlying relative immunosuppression cannot directly targeted poorly codified mostly based surgery radiotherapy localized aggressive form visceral involvement treated chemotherapy interferon give best transient response may well tolerated elderly talimogene laherparepvec first oncolytic immunotherapy approved fda metastatic unresectable melanoma injectable nodal cutaneous lesion designed induce tumor regression injected lesion direct lytic effect uninjected lesion induction systemic antitumor immunity merkel cell carcinoma mcc another virus induced tumor pharmacodynamic pharmacodynamic axis inhibitor proven efficacy thus providing proof principle immunotherapy could effective virus induced tumor two case metastatic mcc succesfully treated talimogene laherparepvec recently reported suggesting talimogene laherparepvec may also effective therapeutic option considering high immunogenicity viral epitope tumor role immune evasion development cutaneous manifestation easily injected classic endemic good tumor model targeted talimogene laherparepvec main objective assess whether talimogene laherparepvec clinically inactive partial complete response probability truly active partial complete response probability classic endemic kaposi sarcoma endpoint best overall response rate borr defined occurrence complete response partial response injected lesion following pga criterion pga recorded start beginning specific therapy kaposi sarcoma occurs objective safety profile talimogene laherparepvec classic endemic kaposi sarcoma parameter efficacy best response response rate duration response efficacy injected uninjected lesion quality life exploratory objective characterize efficacy talimogene laherparepvec related immunologic viral assessment tumor biopsy blood sample endpoint adverse event following common terminology criteria for adverse events borr according actg criterion response rate response rate lymphedema time response duration response response injected uninjected target lesion death cause adapted dlqi score exploratory endpoint characterize immune tumor infiltrate immune cell quantification viral infiltrate tumor necrosis hhv viral load blood tumor cell hhv sequencing ii multicentre single arm open label adult classic endemic histologically confirmed kaposi sarcoma progressive require systemic therapy injectable measurable disease defined least cutaneous lesion millimeter largest diameter previously irradiated field least cutaneous lesion millimeter largest diameter available repeated cutaneous biopsy previously irradiated field nb cutaneous lesion replaced cluster small lesion edge edge distance millimeter biggest diameter cluster meet previous criterion willing provide tissue cutaneous biopsy least week washout specific therapy including topical chemotherapy radiotherapy immunotherapy including interferon provide written prior performance specific procedure age day signing performance status eastern cooperative oncology group (= performans status (= ecog)) performance scale demonstrate adequate organ function haematological absolute neutrophil count absolute neutrophil count millimeter platelet millimeter haemoglobin deciliter renal serum creatinine upper limit normal upper limit of normal calculated creatinine clearance ml min using mdrd formula subject creatinine level upper limit of normal hepatic aspartate amino transferase serum glutamic oxaloacetictransferase alanine amino transferase serum glutamopyruvatetransferase xuln serum bilirubin xuln direct bilirubin upper limit of normal subject bilirubin level xuln pt ptt tca female subject childbearing potential negative serum pregnancy within hour prior receiving first dose medication health insurance known history organ transplantation including allogeneic stem cell transplantation human immunodeficiency virus human immunodeficiency virus antibody detected selection symptomatic visceral involvement including brain metastasis active autoimmune disease requires systemic required systemic past use disease modifying agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc considered form systemic vitiligo type diabetes mellitus hypothyroidism psoriasis non requiring systemic permitted enrol evidence clinically significant immunosuppression following immunodeficiency state severe combined immunodeficiency disease concurrent opportunistic infection receiving systemic immunosuppressive therapy including oral steroid dos milligrams day prednisone equivalent within day prior enrolment clinically significant cardiac dysfunction symptomatic heart failure clinically significant arrhythmia conduction disorder active herpetic skin lesion prior complication hsv infection eg herpetic keratitis encephalitis intermittent chronic systemic intravenous oral antiherpetic drug eg acyclovir intermittent topical use previous talimogene laherparepvec oncolytic virus prior radiotherapy field overlap injection site prior immunosuppressive chemotherapy radiotherapy biological cancer therapy major surgery within day prior enrollment recovered common terminology criteria for adverse events grade better adverse event due therapy administered day prior enrollment prior therapy tumor vaccine received live vaccine within day prior enrolment currently another investigational device drug less day since ending another investigational device drug acute chronic active hepatitis hb ag detected infection hcv rna detected active tuberculosis bacillus tuberculosis known additional malignancy currently progressing requires active within last exception include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer sensitivity product component administered psychiatric substance abuse disorder would interfere cooperation requirement pregnant breastfeeding expecting conceive father child within projected duration last dose talimogene laherparepvec subject unwilling minimize exposure blood body fluid individual higher hsv induced complication immunosuppressed individual individual known human immunodeficiency virus infection pregnant woman infant age talimogene laherparepvec day last dose talimogene laherparepvec pregnant breastfeeding expecting conceive father child within projected duration female subject childbearing potential unwilling use acceptable method effective contraception last dose talimogene laherparepvec sexually active subject partner unwilling use male female latex condom avoid potential viral transmission sexual contact within day talimogene laherparepvec addition male participant donate sperm last dose vulnerable subject prisoner incarcerated following administrative court decision subject psychiatric disorder involuntary hospitalized subject legal protection measure subject cannot express talimogene laherparepvec dose pfu ml week ml week every week ml injection route intralesional injection duration cycle immunovirologic evaluation based tumor tissue collection cutaneous biopsy correlative blood sampling kaposi sarcoma enrolled first part another second part implies screen maximum national multicenter site follow screening cycle follow duration saint louis cochin simon stage optimal design interim analysis planned",
  "MAC-HAPLO-MUD": "randomized prospective iii comparing human leukocyte antigen matched unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative conditioning regimen unrelated adult donor human leukocyte antigen matched recipient allele level human leukocyte antigen dqb drb considered best choice absence human leukocyte antigen matched sibling needing hematopoietic stem cell transplantation sct however using matched unrelated donor mud limited prolonged time identify schedule donation mud allowing relapse transplantation performed limited availability fully human leukocyte antigen mud non caucasian population alternative donor single human leukocyte antigen mismatched unrelated donor unrelated umbilical cord blood graft haploidentical related donor still associated higher non relapse mortality delayed immune reconstitution recent strategy haploidentical haplo related donor sct haplo sct improved dramatically outcome using cell replete graft administration post transplantation cyclophosphamide ptcy target alloreactive cell generated early human leukocyte antigen mismatched transplant sparing regulatory cell leaving unaffected non dividing hematopoietic stem cell standard post transplant immune suppression calcineurin inhibitor cni mycophenolate mofetil retrospective haplo sct ptcy associated similar overall progression free survival mud stem cell transplantation mud sct lower rate toxicity graft versus host disease graft versus host disease thus potentially better result mud sct reduced intensity conditioning regimen iii randomized currently addressing question france elderly using reduced intensity conditioning regimen haplomudelederly programme hospitalier de recherche clinique principal investigator blaise institut paoli calmettes randomized prospective iii comparing human leukocyte antigen mud haplo sct myeloablative conditioning regimen urgently needed answer question main objective improve progression free survival without acute grade ii intravenous infusion graft versus host disease without moderate severe chronic graft versus host disease using haplo donor compared human leukocyte antigen mud myeloablative sct endpoint progression free survival without grade ii intravenous infusion acute graft versus host disease without moderate severe chronic graft versus host disease haplo sct versus human leukocyte antigen mud objective compare two arm term biological outcome kinetic haematopoietic reconstitution graft failure graft versus host disease progression free survival relapse non relapse mortality overall survival interval transplant rehospitalizations related morbidity quality life chimerism immune reconstitution search prognostic factor main outcome globally arm search covariate interaction main outcome endpoint interval transplant absolue number neutrophil platelet chimerism acute graft versus host disease incidence grading chronic graft versus host disease incidence grading relapse incidence progression free survival severe infection ctc adverse event grade incidence veino occlusive disease incidence cardiac toxicity non relapse mortality overall survival quality life questionnaire ebmt number new day hospitalization hospitalization transplantation immune reconstitution lymphocyte cd cd nk lymphocyte gammaglobulines randomized prospective iii comparing human leukocyte antigen matched unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative conditioning regimen age older high hematological malignancy indication allogeneic hematopoietic stem cell transplantation aged old acute myeloid leukemia smd smp requiring allogeneic stem cell transplantation least partial response malignant disease without human leukocyte antigen matched related donor strong probability related haplo donor human leukocyte antigen matched donor available need least mud identified outside book bmdw bone marrow donor worldwide using easy match software included usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase bilirubin creatinine mol except abnormality linked hematological disease health insurance coverage understand optimal follow prescription two effective contraception method must prescribed duration signed written parent aged less cancer last except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus htlv active hepatitis yellow fever vaccine heart failure according “new york heart association” ii bile duct obstruction preexisting acute hemorrhagic cystitis renal failure creatinine clearance ml min pregnancy hcg positive breast feeding debilitating medical psychiatric illness preclude realization sct understanding protocol protection law tutorship curatorship unwilling unable comply protocol haplo donor myeloablative sct use cyclophosphamide milligrams kilograms day intravenous route stem cell transplantation human leukocyte antigen mud myeloablative sct conditioning regimen myeloid malignancy haploidentical sct thiotepa milligrams kilograms day day fludarabine milligrams day day intravenous infusion busulfan milligrams kilograms day day human leukocyte antigen matched unrelated donor sct fludarabine milligrams day day intravenous infusion busulfan milligrams kilograms day fludarabine milligrams day day body irradiation cgy twice daily day dose cgy stem cell source bone marrow haploidentical sct peripheral blood stem cell pbsc human leukocyte antigen matched unrelated transplantation graft versus host disease prophylaxis haploidentical sct cyclophosphamide milligrams kilograms day ciclosporine mycophenolate mycophenolate mofetil human leukocyte antigen matched unrelated donor sct anti thymocyte globuline thymogobuline milligrams kilograms dose milligrams kilograms day cyclosporine day mycophenolate mofetil day absence graft versus host disease mycophenolate mofetil stopped arm randomization donor haplo mud blood sample biobanking related sct randomization haplo mud arm difference arm goal show superiority haplo sct endpoint even similar result arm obtained might revolutionize strategy sct since haplo donor used priority compared mud quick procedure cheaper available almost centre duration centre justification sample size hypothesize progression free survival without grade ii intravenous infusion acute graft versus host disease without moderate severe chronic graft versus host disease haplo sct versus human leukocyte antigen mud arm overall required demonstrate difference based two sided logrank test power high required number event bayesian interim analysis inflate interim analysis mid based bayesian computation stopping rule based modeling log hazard ratio high main endpoint spiegelhalter non informative prior loghr considered terminal analysis observation required number event",
  "APARR": "evaluation optimized allogeneic hematopoietic stem cell transplantation protocol post transplant cyclophosphamide aged old acquired aplastic anemia refractory relapse immunosuppression hematopoietic stem cell transplantation hematopoietic stem cell transplantation major therapeutic option acquired aplastic anemia aa improved survival achieved younger old thanks better donor selection conditioning regimen graft versus host disease prophylaxis together improved supportive care however never case age overall survival hematopoietic stem cell transplantation never exceeded using available sibling unrelated donor ref thus standard immunosuppressive therapy ist associating cisclosporine horse anti thymocyte globuline together addition eltrombopag epag considered standard care adult older aa ref indeed outcome refractory first line ist remain poor lack non transplant poor result transplantation age ref past decade significant decrease infection related mortality population initial ist hemorrhage long term fatigue still present moreover clonal evolution including paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome md acute myeloid leukemia acute myeloid leukemia still occur long term grim prognosis md acute myeloid leukemia ref overall survival adult acquired aa refractory relapse ist outside hematopoietic stem cell transplantation thus ref recently new strategy prevent acute chronic graft versus host disease including cell replete graft administration post transplantation cyclophosphamide ptcy revolutionized field change extended option hematopoietic stem cell transplantation refractory relapse aa lack human leukocyte antigen matched donor ref recently optimized baltimore protocol using ptcy strategy also appears improve engraftment reduce graft versus host disease graft versus host disease classical setting sibling matched unrelated hematopoietic stem cell transplantation outside aa ref one first cause death hematopoietic stem cell transplantation older age refractory relapse aa graft versus host disease use optimized baltimore protocol type donor haplo also sibling matched unrelated transplantation within field aa rapidly appears promising ref using optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy haplo identical donor setting also case available matched sibling unrelated donor might prevent drastically graft versus host disease eventually practice changing evaluating new transplant protocol new strategy main objective aparr main objective demonstrate benefit term grfs graft versus host disease graft versus host disease graft failure free survival historical rate refractory relapse aa undergoing hematopoietic stem cell transplantation ref using optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy old haplo identical donor setting endpoint grfs following hcst composite endpoint measured time hematopoietic stem cell transplantation first following event graft failure grade acute graft versus host disease severe chronic graft versus host disease death objective demonstrate benefit term biological outcome graft failure mortality overall survival quality life related morbidity notably severe infection cardiac toxicity chimerism immune reconstitution endpoint day engraftment consecutive day neutrophile consecutive day platelet donor chimerism blood absolute number neutrophil platelet day last platelet red blood cell transfusion acute graft versus host disease incidence grade chronic graft versus host disease incidence severe chronic graft versus host disease graft failure severe infection common terminology criteria for adverse events grade incidence cardiac toxicity incidence cmv ebv infection mortality overall survival quality life questionnaire pre transplant chimerism immune reconstitution lymphocyte cd cd nk lymphocyte gammaglobulines ii multicenter national prospective single arm aged refractory relapse aa ist eligible hematopoietic stem cell transplantation aged old suffering acquired refractory severe idiopathic aplastic anemia least anti thymocyte globulin cyclosporine eltrombopag relapse allograft validated national multidisciplinary expertise meeting french reference centre aplastic anemia available geno identical donor matched donor haploidentical donor absence donor specific antibody detected mfi antibody distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase conjugated bilirubin bilirubin available clearance creatinine ml min health insurance coverage woman childbearing potential men must use contraceptive method research last dose cyclophosphamide respectively signed written nb authorized contraceptive method woman childbearing potential absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable transdermal progestogen hormonal contraception intrauterine hormonal releasing system ius sexual abstinence need evaluated relation duration preferred usual lifestyle participant men absence permanent sterilization sexual abstinence condom individual must meet criterion verified screening visit eligible participate morphologic evidence clonal evolution isolated bone marrow cytogenetic abnormality also eligible excepted chromosome abnormality complex karyotype seropositivity human immunodeficiency virus htlv active hepatitis associated hepatic cytolysis cancer last except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breast feeding yellow fever vaccine others live virus vaccine within transplantation research uncontrolled coronary insufficiency recent myocardial infarction current manifestation heart failure according “new york heart association” ii ventricular ejection fraction renal failure creatinine clearance ml min contraindication mentioned smpc investigator brochure medicinal product planned used including conditioning regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis known allergy intolerance medicinal product excipients planned used including conditioning regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis according investigator brochure smpc debilitating medical psychiatric illness precludes understanding inform well optimal follow legal protection tutorship curatorship state medical aid another interventional medicinal product cell therapy individual meeting exclusion criterion verified screening visit ineligible participate conditioning regimen thymoglobulin milligrams kilograms milligrams kilograms milligrams kilograms fludarabine milligrams day day day pre transplant cyclophosphamide milligrams kilograms day day day body irradiation gray day stem cell source bone marrow target nucleated cell kilograms recipient body weight granulocyte colony stimulating factor given subcutaneously starting day milligrams kilograms day absolute neutrophil count greater day graft versus host disease prophylaxis cyclophosphamide milligrams kilograms day tacrolimus milligrams kilograms day per divided dos milligrams kilograms ivse mycophenolate mycophenolate mofetil begin absence graft versus host disease mycophenolate mofetil stopped tacrolimus day prevention ebv reactivation rituximab milligrams intravenously day post hematopoietic stem cell transplantation except donor ebv serology ebv pcr negative infusion rituximab preceded administration anti pyretic antihistaminic paracetamol diphenhydramine nb however permissible delay administration rituximab hour occurs sunday greater safety discretion investigator additional test specific examination except quality life questionnaire rituximab considered added research provided sponsor outcome adult refractory relapse aa older remain poor hematopoietic stem cell transplantation sole therapeutically valid option result always disappointing transplantation currently rarely possible optimized hematopoietic stem cell transplantation protocol haplo identical donor setting also case available matched sibling unrelated donor might prevent graft versus host disease eventually drastically improve outcome hematopoietic stem cell transplantation older refractory relapse aa direct benefit since curative safe option available far absence transplantation aged refractory relapse aa ist thus exposed infection hemorrhage prolonged fatigue also long term clonal evolution including paroxysmal nocturnal hemoglobinuria pnh well myelodysplastic syndrome md acute myeloid leukemia acute myeloid leukemia grim prognosis global health care benefit also possible since wont need medical support including hospitalization also daily hospital care antibiotic need transfusion rituximab injection level indication hematopoietic stem cell transplantation refractory relapse aa aged refractory relapse first line ist center affiliated sfgm tc france bmt follow duration centre sample size calculation two sided one sample log rank test calculated sample subject achieves power significance level detect grfs new group grfs historic control group followed analysis endpoint several interim analysis outcome measure planned every unless less enrolled based bayesian approach end accrual follow grfs estimated using kaplan meier method corresponding confidence interval compared historical rate using one sample two sided log rank test additional terminal analysis use external observational cohort propensity score weighting ensure unbiased comparison enhance level evidence effect",
  "HAPLO-EMPTY": "haploidentical allogeneic hematopoietic stem cell transplantation post transplant cyclophosphamide acquired refractory aplastic anemia nationwide ii outcome severe aplastic anemia saa refractory first line immunosuppressive therapy ist lack matched unrelated donor mud remain poor recently use eltrombopag elt shown blood count improvement however refractory respond elt second line therefore exposed life threatening infection bleeding past decade significant decrease infection related mortality saa unresponsive initial ist clonal evolution including paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome md acute myeloid leukemia acute myeloid leukemia still occur long term grim prognosis overall overall survival acquired refractory saa elt hematopoietic stem cell transplantation hematopoietic stem cell transplantation using alternative donor source mismatched unrelated donor cord blood cbt haplo identical family donor may curative refractory saa despite carrying much higher rate complication transplantation matched related unrelated donor recently group showed cbt valuable curative option young adult refractory saa however available cb cbt related mortality high adult haploidentical haplo related donor stem cell transplantation haplo sct improved dramatically outcome using cell replete graft administration post transplantation cyclophosphamide ptcy preliminary result little number refractory saa king college london uk john hopkins baltimore usa seem promising retrospectively analyzed data median age transplanted europe behalf saa working party european blood marrow transplantation group overall survival suggesting approach might valid option particular poor situation main objective demonstrate benefit term overall survival rate historical rate acquired refractory idiopathic aplastic anemia using haplo sct ptcy endpoint overall survival rate objective biological outcome graft failure graft versus host disease graft versus host disease progression free survival relapse non relapse mortality overall survival quality life chimerism immune reconstitution endpoint graft failure incidence neutrophil platelet engraftment day consecutive day neutrophile consecutive day platelet absolute number neutrophil platelet day last platelet red blood cell transfusion incidence use growth factor poor hematopoietic reconstitution acute graft versus host disease incidence date maximum grading first line response steroid course case steroid refractory graft versus host disease chronic graft versus host disease incidence date grading relapse incidence progression free survival incidence cmv ebv infection severe infection ctae grade non relapse mortality incidence cardiac toxicity overall survival quality life questionnaire post transplantation chimerism immune reconstitution analyzing nk regulatory cell level peripheral blood post transplantation ferritin level ii multicenter national prospective cohort aged acquired refractory idiopathic aplastic anemia indication haploidentical allogeneic hematopoietic stem cell transplantation aged old suffering refractory acquired idiopathic aplastic anemia least one course immunosuppression anti thymocyte globulin absence geno identical donor matched donor identification haploidentical donor brother sister parent adult child cousin absence donor specific antibody detected mfi antibody directed towards distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase bilirubin creatinine mol health insurance coverage contraception method must prescribed duration research woman men childbearing age must use contraceptive method within last dose cyclophosphamide respectively signed written parent aged less nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable transdermal progestogen hormonal contraception intrauterine hormonal releasing system ius sexual abstinence need evaluated relation duration preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom morphologic evidence clonal evolution isolated bone marrow cytogenetic abnormality also eligible uncontrolled infection seropositivity human immunodeficiency virus htlv active hepatitis defined positive pcr hbv hcv associated hepatic cytolysis cancer last except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breast feeding received attenuated vaccine within transplantation uncontrolled coronary insufficiency recent myocardial infarction current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction heart failure according “new york heart association” ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance ml min urinary tract obstruction contraindication treatment used research debilitating medical psychiatric illness preclude understanding inform well optimal follow tutorship curatorship conditioning regimen fludarabine milligrams day day day pre transplant cyclophosphamide milligrams kilograms day day day body irradiation gray day stem cell source bone marrow graft versus host disease prophylaxis rabbit anti thymoglobulin dosed milligrams kilograms day milligrams kilograms day cyclophosphamide milligrams kilograms day tacrolimus residual microg mycophenolate mycophenolate mofetil absence graft versus host disease mycophenolate mofetil stopped tacrolimus day prevention ebv reactivation rituximab milligrams intravenously day post hematopoietic stem cell transplantation infusion rituximab preceded administration anti pyretic antihistaminic paracetamol diphenhydramine additional test specific examination outcome saa refractory first line ist lack mud remain poor transplantation sole therapeutically valid option cbt valuable curative option young adult mortality using approach high adult cb always available haplo sct ptcy recently showed promising result situation nearly available haplo donor biologic parent child haplo sibling chance haplo moreover haplo sct ptcy available almost also quick cheap procedure might thus demonstrate haplo sct ptcy curative option adult refractory aplastic anemia child young cbt available related sct cardiac toxicity hemorrhagic cystitis particularly monitored indication allograft context acquired refractory aplastic anemia objective allo grafted anticipate include centre france post transplant duration centre centre justification sample size hypothesize overall survival versus historical control two sided one sample logrank test calculated sample subject achieves power significance level detect proportion new group proportion historic control group terminal analysis realized observation required number event"
}